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Abstract

Atherosclerosis is both a chronic inflammatory disease and lipid deposition
disorder characterized by accumulation of lipids, fibrous tissue, and inflammatory
cells in the arterial wall. Thus, investigating the role of inflammation and the
immune system in the progression of atherosclerosis may help in the development
of novel therapeutics for atherosclerotic disease. Current atherosclerosis therapy
is aimed at lipid targets and focused primarily on reducing plasma cholesterol
levels. Clinical and experimental data support the critical role of inflammation in
atherosclerosis and suggest that reducing inflammation even without affecting lipid
levels may reduce the event rate of cardiovascular disease. Yet, no pure antiinflammatory drugs are used to treat patients with atherosclerotic diseases.
Recently, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study
(CANTOS) provided evidence that targeting inflammation by inhibiting IL1-β
reduced the rate of cardiovascular events, providing support for the inflammation
hypothesis of atherosclerosis. In this study, we aim to test the inflammation
hypothesis using various immunomodulatory approaches. First, we measured the
expression of inflammation markers in human atherosclerotic carotid arteries. We
demonstrated that markers of inflammation were significantly increased in plaques
compared to normal media and those markers positively correlate with miR155, a
pro-inflammatory microRNA. We observed that miR155 was up-regulated in the
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calcified media occurred concomitant with osteogenic genes; and cell culture and
mouse studies further suggested a causal role of miR155 in vascular calcification.
In the second study we observed that bone marrow tristetraprolin (TTP) deficiency
in LDLR−/− mice significantly increased systemic inflammation. Unexpectedly,
serum lipid levels and hepatic steatosis were dramatically reduced, likely due to
reduced lipid production in the liver by downregulating SREBF1. Increased
inflammation and reduced serum lipid offset each other and result in unchanged
atherosclerosis. This model may provide an opportunity to examine the
relationship between inflammation and lipoprotein metabolism. We also
investigated the effect of macrophage-specific GP96 deficiency on atherosclerosis
to determine the role of toll like receptors (TLRs) during atherogenesis. Our results
show that macrophage-specific GP96 deficiency did not change inflammatory
status, serum lipid, and atherosclerosis in LDLR−/− mice. Sparstolonin (SsnB), a
selective TLR2/TLR4 inhibitor, is known to have anti-inflammatory effects. In this
study, we injected mice with super-low dose LPS or LPS plus SsnB. Super-low
dose LPS increased serum chemo-attractants, while SsnB reduced these
chemokines. However, super-low dose LPS and SsnB administration did not affect
atherosclerotic lesions. Atherosclerosis is a complex, multifactorial process, and
the interaction between inflammation and atherogenesis is complicated as
indicated by our results. Since CANTOS shows that targeting inflammation
reduced the rate of cardiovascular events, it opens the field to further examine the
inflammation hypothesis of atherosclerosis and to explore novel therapeutic
avenues by targeting inflammation.
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Chapter I
Introduction
1.1 Atherosclerotic cardiovascular diseases
Cardiovascular diseases (CVDs), including myocardial infarction (heart
attack) and angina pectoris (chest pain), represent the leading causes of mortality
and long-term morbidity worldwide1. The incidence of CVDs continues to rise and
is projected to remain as the number one cause of death globally by 2020 2.
Atherosclerosis is by far the main underlying pathological process of coronary
artery disease, carotid artery disease, and peripheral arterial disease — which are
among the most prevalent CVDs3.
The term ‘atherosclerosis’ comes from Greek word "athero" meaning gruel,
and sclerosis means hard — which is hardening with loss of elasticity leading to
narrowing of the arteries. Atherosclerosis is both a lipid deposition disorder and a
chronic inflammatory disease, characterized by formation of atherosclerotic plaque
in the arterial wall4,5. It mainly affects medium-sized and large arteries such as: the
aorta, coronary arteries, carotid arteries, and renal arteries, in focal areas —
particularly regions in which laminar flow is disturbed (e.g. arterial branch points
and bifurcations)6,7. The disease begins early in life and goes undetected until
thrombotic complications, such as acute coronary syndromes and stroke occur8.
There are numerous genetic and environmental risk factors associated with
atherosclerotic diseases. Most of the environmental risk factors are modifiable and
1

reversible, whereas the genetic factors are not. Clinically significant lesions are
usually associated with hypercholesterolemia, smoking, diabetes mellitus,
hypertension, obesity, physical inactivity, family history, and high-fat diet (HFD)8-9.
It has been shown that hypercholesterolemia alone is sufficient to drive the
development of atherosclerosis. However, the presence of other risk factors
appears to accelerate disease progression, driven by the atherogenic lipoproteins
(i.e. low-density lipoprotein; LDL)10.
1.2 Structure of blood vessel wall
The normal wall of blood vessels consists of endothelial cells, vascular
smooth muscle cells (VSMCs), and extracellular matrix (ECM) arranged in three
different layers (from innermost to the outermost): the intima, media, and
adventitia11. The tunica intima is composed of a single monolayer of simple
squamous cells known as endothelial cells. It lies on the internal elastic lamina, a
layer of elastic fibers, which defines the outermost boundary of the intimal space
and separates the intima from the media. The endothelial layer represents the
interface between circulating blood flow and the vascular wall — providing a
smooth lining for blood vessels12. The endothelial cells have a significant role in
regulation of vascular permeability, regulation of immune responses, modulation
of blood flow and vascular resistance, platelet aggregation, and thrombosis
prevention. These are achieved by releasing anti-platelet, anti-coagulant, antithrombogenic, and fibrinolytic factors in addition to the production of the potent
vasodilator nitric oxide (NO)13. Besides the vasodilators, endothelial cells also
produce some vasoconstrictor molecules, such as endothelin and angiotensin-II,
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which can also promote proliferation of smooth muscle cells and thereby contribute
to plaque formation14,15. Therefore, the ability of the endothelial cell layer to repair
itself and to maintain functional and structural integrity, is key to the prevention of
atherosclerosis16,17.
The middle layer of the arterial wall is the tunica media, which is composed
primarily of VSMCs surrounded by a network of ECM proteins including elastic
fibers, collagen, and proteoglycans. This layer provides strength and elasticity to
the blood vessels so they can stretch or expand without tearing18. The outermost
layer is the tunica adventitia, which is primarily composed of irregularly arranged
collagen bundles, scattered fibroblasts, a few elastic fibers, and small blood
vessels called vasa vasorum. Vasa vasorum provides oxygen and nutrients to
outer layers of the vascular wall. The elastic collagen fibers allow arteries to stretch
to prevent over-expansion due to higher pressures in these blood vessels19-20.
Understanding the structure and function relationship of each layer in the arterial
wall provides insight into the pathophysiology of arterial wall diseases, such as
atherosclerosis, and allows for better predictions for prevention and treatment
strategies.
1.3 Pathogenesis of atherosclerosis
Atherosclerosis is a complex and multifactorial disease characterized by
systemic and vascular wall inflammation and activation of immune pathways,
dyslipidemia, endothelial dysfunction, foam cell formation, VSMC activation,
platelet activation, and thrombosis21,22. A number of hypotheses have been
proposed to describe the pathogenesis of atherosclerosis including the: response
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to injury hypothesis23, response to retention hypothesis24, LDL-oxidation
hypothesis25,

lipid hypothesis26,

and

inflammation

hypothesis27. A

better

understanding of the pathogenesis of atherosclerosis will aid in formulating
preventive and therapeutic strategies to reduce the mortality rate of cardiovascular
events.
1.3.1 Response to injury hypothesis
The response to injury hypothesis suggests that atherosclerosis is initiated
with injury-induced damage and dysfunction of the endothelial cells lining the
intima. This damage caused by local disturbances of blood flow at branch points,
along with systemic risk factors, perpetuates a series of events that culminate in
the development of atherosclerotic plaque. Endothelial dysfunction is the initial
step that allows entry and retention of cholesterol-containing LDL particles and
inflammatory cells (i.e. monocytes, T lymphocytes) into the sub-endothelial
spaces,

altering

normal

homeostasis28,29,30.

Under

normal

homeostatic

conditions, the white blood cells do not adhere to the endothelial cells lining the
intima. However, under atherogenic conditions, the damaged endothelial cells
express surface adhesion molecules such as vascular adhesion molecule-1
(VCAM-1), leading to adhesion of circulating blood monocytes to the endothelial
surfaces. Those monocytes ultimately migrate to the sub-endothelial space. When
acting together with imbalance between vasoconstriction and vasodilation, these
processes promote increased vascular permeability and platelet aggregation31.
Furthermore, endothelial dysfunction is associated with decreased production of
NO and increased cellular permeability to lipoproteins, each thought to be a key
event in the development and progression of atherosclerosis32.
4

1.3.2 Response to retention hypothesis
The response to retention hypothesis of atherosclerosis was initially
proposed in 199524. Since then there has been several line of experimental
evidence supporting this hypothesis. The response to retention hypothesis
suggests that retention of cholesterol-rich, atherogenic lipoproteins within the subendothelial space is the key initiating event in early atherosclerosis. Once retained,
these lipoproteins increased susceptibility for modification/oxidation, and
subsequently provoke the inflammatory response with increasing smooth muscle
cell migration and phenotype switching as well as infiltration of inflammatory cells
including macrophages24,30.
1.3.3 LDL oxidation hypothesis
The LDL oxidation hypothesis suggests that oxidative modification of
lipoproteins, in particular LDL, within the arterial wall by reactive oxygen species
(ROS) plays an important role in the pathogenesis of atherosclerosis25.
Monocytes/macrophages express scavenger receptors that engulf oxidized oxLDL
in an uncontrolled manner. In turn, uptake of oxLDL leads to accumulation of lipids
and lipid-laden foam cells to form a fatty streaks — an early feature of
atherosclerotic plaque formation25,33,34. Experimental data indicate that oxLDL
within the arterial wall promotes the development of atherogenesis25. Additionally,
inhibiting the oxidation of LDL could decrease or prevent atherosclerosis
development. Previous studies have shown the efficacy of anti-oxidant treatment,
such as probucol and vitamin E, which significantly reduced the severity of
atherosclerosis in different atherogenic animal models. These studies supported
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the oxidative modification hypothesis35. Furthermore, targeting some proteins
involved in LDL oxidation and uptake of oxLDL (e.g. 12/15 lipoxygenase and
scavenger receptors (SRA and SRB)) in various atherogenic murine models
significantly attenuated the severity of atherosclerosis36–38.
1.3.4 Lipid hypothesis
The lipid hypothesis of atherosclerosis states that both lesion initiation and
progression of atherosclerosis is primarily associated with hyperlipidemia26. In the
last decade, considerable advances in the understanding of cardiovascular risk
factors have been established, and dyslipidemia has been shown as one of the
most powerful risk factors. Controlling blood cholesterol is efficient at reducing
cardiovascular risk and an important therapeutic decision, as the rate of CVDs
were significantly reduced with decreased blood cholesterol39. The link between
hyperlipidemia and atherosclerosis predominate, until the 1970s, based on strong
experimental and clinical relationships between hypercholesterolemia and severity
of atherosclerotic lesions. This was further supported by the fact that statins, lipid
lowering agents, were able to significantly reduce atherosclerotic diseases40.
The first description of an atherosclerotic lesion was recorded in 1908 when
Alexander I. Ignatowski, an experimental pathologist, fed rabbits cholesterol for 17
weeks followed by chow diet for 14 weeks. These rabbits developed pronounced
aortic atherosclerosis41. In 1913, Anitschkow and colleagues proposed the
fundamental role of cholesterol in the pathogenesis of atherosclerosis. They fed
rabbits with a high-cholesterol diet and found that the blood cholesterol levels were
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significantly increased, and indeed, within weeks those rabbits displayed vascular
atherosclerotic lesions similar to those of human atherosclerosis42.
In order to examine the lipid hypothesis of atherosclerosis induced by
cholesterol, Clarkson and Newburgh (1926) fed rabbits a normal diet with various
cholesterol doses for 47- 87 days. They discovered atherosclerosis in rabbits fed
high cholesterol doses43. These observations strongly supported the theory that
cholesterol was the main driving force in the development of atherosclerotic
CVDs44.
In the early stages of atherosclerosis, plasma LDL crosses the endothelial
barrier and enters the intima. Once accumulated in the sub-endothelial arterial
intima, LDL undergoes oxidative modification via the reactive oxygen species
produced by macrophages and damaged endothelial cells, forming oxLDL34,22,45.
oxLDL is a pivotal molecule representing the initial event in atherosclerotic lesion
formation and progression by promoting inflammation, foam cell formation, and
smooth muscle cell migration/proliferation46. oxLDL is also considered a potent
chemo-attractant and strong pro-inflammatory stimulus, which recruits the
circulating blood monocytes and T-cells to the sub-endothelial space47. Once
retained in the intima, oxLDL activates endothelial cells and up-regulates the
expression of adhesion molecules, such as VCAM-1 and intercellular adhesion
molecule-1 (ICAM-1), and the secretion of chemokine/cytokines that contribute to
the recruitment of circulating leukocytes48,49. oxLDL taken up by activated
macrophages via scavenger receptors (SR-A, CD36, and Lox1) form lipid-laden
foam cells — a hallmark of atherosclerosis. Activated macrophages and foam cells
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secrete different pro-inflammatory cytokines and chemokines, which in turn attract
more monocytes to the intima and potentiate the inflammatory response 22,31,50.
The role of plasma lipoproteins in atherosclerosis development has gained
significant attention and has been demonstrated by randomized controlled trials.
These studies revealed the rate of cardiovascular events were significantly
reduced via inhibition of cholesterol biosynthesis using lipid lowering agents,
mainly statins. Statins act by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase (HMG-CoA Reductase); the rate limiting step in the cholesterol
biosynthesis pathway40. The lipid hypothesis of atherosclerosis is now considered
fact, supported by: 1) epidemiological studies that have shown a positive
relationship between total cholesterol concentrations and the mortality rate of
CVDs, and 2) the success of statin drug therapy in the past 40 years; statins
significantly reduced atherosclerotic disease mortality through reducing plasma
LDL levels39.
1.3.5 Inflammation hypothesis
In the last century, it was believed that atherosclerosis was merely a lipid
storage disease, associated with hyperlipidemia and accumulation of cholesterol
and fatty streaks in the arterial wall. Over the past two decades, studies
demonstrated the complexity of atherosclerosis and the involvement of both the
innate and adaptive immune systems by detecting different immune cells (e.g.
monocytes, macrophages, dendritic cells (DCs) and T cells) associated with
production of immune mediators within the arterial wall21. Presently, the role of
inflammation in atherosclerosis is well recognized and accumulating evidence
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indicates that inflammation plays a key role in the pathophysiology of all stages of
atherosclerosis from lesion initiation, through progression, and ultimately the
thrombotic complications of atherosclerosis51.
Inflammation in the arterial wall proceeds as a cascade, which begins with
endothelial cell activation and expression of surface adhesion molecules such as
VCAM-1, ICAM-1, selectins, and integrins that increase the adhesion of circulating
blood monocytes to the endothelial cell layer lining the blood vessel
wall52,53. Furthermore, the activated endothelial cells will secrete chemoattractants, such as monocyte chemoattractant protein-1 (MCP-1) also known as
CCL2, that interact with chemokine receptors on blood monocytes and promote
their recruitment and entry into sub-endothelial intimal space in a phenomenon
known as diapedesis54,55,56. Once the blood monocytes migrate into the subendothelial space, they activate and differentiate into macrophages, stimulated by
macrophage

colony

stimulating

factors

(M-CSF)57–59.

These

activated

macrophages exhibit high expression levels of surface recognition receptors called
scavenger receptors (SR-A and CD36), which have the ability to engulf oxLDL and
form lipid-laden foam cells within the sub-endothelial space. Further, these
activated macrophages secrete inflammatory cytokines/chemokines including
MCP-1, interleukin-1 (IL-1), and tumor necrosis factor-α (TNF-α) that increase
adhesion and recruitment of monocytes into the lesion, potentiating the
inflammatory response of atherosclerosis60,60,61. Over time, the lipid-laden foam
cells coalesce and form a fatty streaks — characteristic of atherosclerosis and
presenting at a very young age. Excessive lipid accumulation followed by
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macrophage death results in enlargement of the atherosclerotic core, deposition
of collagen fibers, and migration of smooth muscle cells from media into the intima.
This ultimately leads to the irreversible formation of fibrous atherosclerotic plaques.
Fibrous lesions usually have a fibrous cap composed of smooth muscle cells and
ECM, which encloses a lipid-rich, necrotic core62. In addition to macrophages,
atherosclerotic lesions contain other immune cells including dendritic cells, B
lymphocytes, and T lymphocytes, notably CD4+ T cells and regulatory T cells,
which regulate many innate immune pathways63–65.
Vascular smooth muscle cells (VSMCs) play a fundamental role in
atherosclerosis

development66.

The

inflammatory

mediators

such

as

cytokines/chemokines and growth factors released by injured endothelial cells and
inflammatory cells stimulate migration of VSMCs from the underlying media to the
sub-endothelial space resulting in intimal area expansion. Additionally, VSMCs will
switch from quiescent contractile phenotype to the proliferative, synthetic
phenotype, characterized by excess production of ECM. This results in deposition
of ECM proteins and formation of a fibrotic cap that covers the necrotic core and
stabilizes/prevents plaque rupture66–69. Over time, these lesions become calcified
and grow toward the adventitia. At a certain point, they begin to encroach to the
lumen leading to narrowing of the blood vessels and the complications associated
with atherosclerosis70.
In the atherosclerotic lesion, monocytes can differentiate into two major
types of macrophages: classically activated (M1) macrophages which promote
inflammation and alternatively activated (M2) macrophages which stimulate
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resolution of inflammation. An imbalance in the ratio of classically versus
alternatively activated macrophages in advanced atherosclerosis leads to impaired
resolution71,72. One important function of M2 macrophages is the clearance of
apoptotic cells via a process called efferocytosis. Efferocytosis is a term refer to
the engulfment or phagocytosis of antigen presenting cells such as macrophages
and dendritic cells73. As macrophages engulf oxLDL in the arterial wall during early
stages of atherosclerosis, these macrophages undergo apoptosis74. Apoptosis is
a physiological, programmed, and energy-dependent cell death cascade. In early
atherosclerosis, macrophage apoptosis is associated with reduced atherosclerosis
progression. This is most likely due to effective efferocytosis by M2
macrophages75,76. Efficient efferocytosis has been shown to induce antiinflammatory mediators, such as interleukin-10 (IL-10) and transforming growth
factor-β (TGF-β)77. As atherosclerosis progresses, efferocytosis is thought to
become impaired. A lack of efferocytosis leads to secondary necrosis, where
macrophages die and release their cellular contents including oxidized lipids and
pro-inflammatory mediators. Secondary necrosis amplifies the inflammatory
response and leads to the development of a necrotic core in the plaque 78.
Additionally, inflammatory cells and VSMCs in the atherosclerotic lesion release
matrix metalloproteinases (MMPs), a family of proteolytic enzymes that degrade
ECM, resulting in the thinning and degradation of the fibrous cap. This promotes
plaque instability, leading to rupture of the atherosclerotic plaque mainly at the
plaque shoulder region and the resultant clinical consequences, such as
myocardial infarction and other thrombotic complications79–81.
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Taken together, it is clear that inflammation indeed drives all phases of
atherosclerosis. Therefore, several anti-inflammatory compounds have been
examined as potential therapeutic strategies for the prevention of atherosclerotic
complications using various atherosclerotic animal models82. Despite strong
evidence arising from animal studies that lowering inflammation may be a
promising strategy for decreasing atherosclerosis and its complications, results
have yet to be recapitulated in humans. Various protein therapeutic strategies,
such as anti-cytokine therapies, have received noticeable appreciation for clinical
application because of their potential direct anti-inflammatory effects. However,
these strategies will require extensive clinical evaluation and testing in randomized
trials before implementation into practice.
There are two large randomized controlled clinical trials testing the
inflammation hypothesis of human atherosclerosis. These studies aim to evaluate
whether inhibiting inflammation will decrease event rates and improve prognosis
among patients with heart disease using anti-inflammatory agents. The
Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) is
evaluating whether interleukin-1β (IL-1β) inhibition by anti-human IL-1β
monoclonal antibody (Canakinumab) can reduce the rates of myocardial infarction,
stroke, and cardiovascular death among patients with a history of previous
myocardial infarction and elevated levels of high-sensitivity C-reactive protein (hsCRP) — a clinical marker for chronic inflammatory conditions83. This study showed
that the hs-CRP was reduced by 39% and reduced cardiovascular event rates by
17%. This study validated the concept that targeting inflammation and
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manipulating the immune system can reduce atherosclerosis without affecting lipid
levels and provide a novel cytokine-based therapy for the secondary prevention of
CVDs84. The second clinical trial that is still on-going is Cardiovascular
Inflammation Reduction Trial (CIRT) which aims to elucidate whether treatment
with low-dose methotrexate (a common drug used in the treatment of autoimmune
disorders such as rheumatoid arthritis and psoriasis arthritis) will reduce major
vascular events among patients with a history of myocardial infarction85.
1.4 Animal models of atherosclerosis
Atherosclerosis animal models have been developed to understand the
cellular and molecular mechanisms of atherosclerosis pathogenesis, and to drive
research that evaluates the efficacy of newly developed preventive and therapeutic
atherosclerotic drugs86. Animal models used to study atherosclerosis and
thrombosis include: mouse, rat, rabbit, and pig87. The majority of animal models
are

based on

the presence

or induction

of

hyperlipidemia, primarily

hypercholesterolemia, which is the most important risk factor influencing
atherosclerosis development. In 1908, Ignatowski demonstrated that the
experimental atherosclerosis could be induced in animals, when he fed rabbits a
diet enriched in animal proteins including milk, eggs, and meat. At the experimental
endpoint, these rabbits presented with atherosclerotic lesions in the aortic wall41,44.
After that, several animal models were employed to understand the mechanisms
involved in both induction and regression of atherosclerotic lesions87,88.
Recently, the mouse models have become the most commonly used animal
model for atherosclerosis experimentation. These animal models are easy to
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handle, inexpensive to maintain, reproduce quickly, and are easily to genetically
manipulate89,90. The development of atherosclerosis in mice is typically based on
genetic modifications of lipoprotein metabolism, including deletion of LDL-receptor
(LDLR) or apolipoprotein-E (apoE) gene, followed by administration of a high fat
diet to induce hyperlipidemia. High-fat diet (HFD) in experimental research has
been found to elevate serum LDL and atherosclerosis in different atherosclerotic
animal models, including mice91. The apoE-deficient (apoE−/−) mice and LDLRdeficient (LDLR−/−) mice are the most widely used murine models92,93.
Apolipoprotein-E is a plasma lipoprotein secreted from liver and promotes hepatic
binding, uptake, catabolism, and clearance of triglyceride-rich lipoproteins such as
very low density lipoprotein (VLDL) and low density lipoprotein (LDL)94. In apoE−/−
mice, the total plasma cholesterol levels are dramatically increased and extensive
atherosclerotic lesions form (widely distributed throughout the aorta) even in the
absence of cholesterol– enriched diet, where lesions progress and advance with
age95. LDLR is a cell-surface receptor expressed in different cell types, where they
pick up low-density lipoproteins circulating in the bloodstream and transport them
into the cell. They are particularly abundant in the liver that mediates the
endocytosis of LDL particles, thereby removing excess LDL-cholesterol from the
circulation. LDLR expression is tightly controlled by feedback mechanisms at the
transcriptional and post-transcriptional levels. When intracellular cholesterol levels
are highly elevated, the transcription factor, sterol regulatory element-binding
proteins (SREBPs) will down-regulate the rate-limiting enzyme of cholesterol
biosynthesis (HMG-COR), as well as the LDLR, and scavenger receptor class B
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member 1 (SCARB1)96. Therefore, LDLR−/− mice exhibit a delayed clearance and
consequently, massive accumulation of plasma LDL93. Thus, the LDLR−/− mouse
model is characterized by elevated plasma cholesterol levels and develop
atherosclerotic lesions slowly when fed a normal chow diet. When fed HFD,
LDLR−/− mice develop hypercholesterolemia and extensive lesions throughout the
entire aorta and aortic root97.
1.5 Bone marrow transplantation and total body irradiation
Lethal total body irradiation of atherosclerotic mice followed by bone marrow
transplantation from donor mice with transgenic alterations in the innate and
adaptive immune systems is a common method utilized to reconstitute the immune
system and experimentally used to identify the role of bone marrow-derived cells
in atherosclerosis. The experimental mice are compared to control mice that have
undergone comparable irradiation and bone marrow transplantation with
syngeneic wild-type bone marrow cells98. This technique is commonly used in
atherosclerosis research to determine the contribution of different hematopoietic
cells of interested genotype to the pathogenesis of atherosclerosis99. The high
dose total body irradiation is to completely deplete the hematopoietic system of the
recipients and to make sure the engraftment of the bone marrow cells from the
donors. Because the total body irradiation causes damage to the small intestine,
the recipient mice should be provided with antibiotics one week before and two
weeks after bone marrow transplantation to avoid septic shock caused by the
intestinal bacteria crossing into the blood stream due to their suppressed immune
system100. LDLR−/− mice are the most common mouse model used as recipient
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mice. ApoE−/− mice are not commonly used as the recipients, because ApoE
produced by the transplanted bone marrow cells are sufficient to reverse the
atherogenic phenotype101. After bone marrow transplantation, mice were allowed
4 – 5 weeks to reconstitute the hematopoietic and immune system. After this
period, majority of the myeloid cells in peripheral blood and bone marrow will be a
donor derived cells98.
1.6 microRNA-155 in atherosclerosis
MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate
gene expression at the post-transcriptional level through base pairing with mRNAs,
resulting in either translational repression or mRNA degradation. The expression
and targets of miRNAs are cell type dependent, which determines the biological
function of miRNAs102,103. microRNA-155 (miR155), a typical multi-functional
miRNA, has recently emerged to play a significant role in atherosclerosis
development104. It has been shown that a hematopoietic miR-155 deficiency
reduced atherosclerosis in partial carotid artery ligation Apoe–/– mouse model by
increasing the expression of B-cell leukemia/lymphoma 6 (Bcl6) in macrophages
thus reducing vascular inflammation105. Additionally, miR155 inhibition by
antagomirs in Apoe–/– mice significantly reduced lesion formation after high-fat diet
feeding106. However, hematopoietic miR155 deficiency increased atherosclerosis
in LDLR−/− mice fed a high-fat diet by generating a more pro-atherogenic immune
cell profile and a more pro-inflammatory monocyte/macrophage phenotype107.
Previously we showed that miR155 deficiency in apoE−/− mice attenuated
atherogenesis by reducing macrophage inflammation108.
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My studies aim to further investigate the inflammation hypothesis of
atherosclerosis in human atherosclerotic carotid lesions as well as in
atherosclerotic mouse models. We measured the expression levels of
inflammation markers in human carotid atherosclerotic lesions and studied the role
of microRNA-155 in vascular calcification. We also studied the role of tristetraprolin
(TTP) in inflammation and atherosclerosis. Additionally, we examined the effect of
macrophage-specific GP96 deficiency on inflammation and atherosclerosis
development. Finally, we examined the therapeutic value of an anti-inflammatory
— Chinese herb compound, SsnB, for atherosclerosis.
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Chapter II
Inflammation markers in human atherosclerotic lesions and the role of
microRNA-155 in vascular calcification
2.1 Background
Inflammation plays a critical role in all stages of atherosclerosis: endothelial
activation resulting in a chemokine-mediated recruitment of different immune cells;
modification and uptake of oxLDL by macrophages and defective cholesterol efflux
leading to formation of foam cells and fatty streaks in the early stage of
atherosclerosis. Over time, the disease progresses and complex fibrotic plaques
are produced as a result of foam cell death, migration and proliferation of VSMCs
and a continued inflammatory response. The production of ECM by VSMCs leads
to stabilization of plaques, whereas the production of matrix metalloproteinases
(MMPs) from macrophages resulted in destabilization and rupture of unstable
plaques and subsequently thrombosis and clinical complications (e.g. myocardial
infarction)31,51,109. The inflammatory response in atherosclerosis is regulated by
both the innate and adaptive immune system coordinated by different cytokines 110.
Knowledge of the roles of cytokines in all stages of atherosclerosis has recently
advanced considerably mainly by studies using mouse model systems 51,110,111.
Therefore, investigating the role of the immune system in the progression of
atherosclerosis and reducing inflammation represent a potential novel therapeutic
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approach for prevention and treatment of atherosclerotic vascular diseases. The
inflammatory cytokine IL1β is the central cytokine in the inflammatory response in
atherogenesis which drives IL6 signaling pathway. The CANTOS study using
Canakinumab, IL-1β neutralizing antibody validated the role of inflammation in
CVDs and revealed a significant 15% reduction of major adverse cardiovascular
events in patient with a prior heart attack and inflammatory atherosclerosis83,84.
The expression of inflammatory markers in human atherosclerotic plaques
has been studied since 1985 using different techniques including RT-PCR,
immunohistochemistry, and in situ hybridization112. Interleukin 1-β (IL-1β) and
interleukin 6 (IL-6) expression have been observed in atherosclerotic lesions in
humans, hypercholesterolemic rabbits, and apoE−/− mice and their roles in nearly
all phases of atherosclerosis have been widely documented, indicating the proinflammatory role of these cytokines113,114. We recently demonstrated a proatherogenic role of microRNA-155 (miR155) in mouse models115. However, if the
pro-atherogenic role of miR155 also holds true in humans has not been examined.
In the current study, we performed qRT-PCR to examine the expression
levels of inflammation markers including — IL-6, IL-1β, miR155, MMP-9,
Adiporedoxin (Adrx) in human atherosclerotic carotid arteries in different locations
— normal media, diseased media, atheroma, and fibrous cap from patients
undergoing surgical carotid endarterectomy. Furthermore, the expression of
miR155 and its correlation to osteogenic genes in calcified media have been
examined. In our study, we demonstrated that most of the inflammatory markers
listed above were significantly up-regulated in atheroma, fibrous cap, and diseased
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media of the carotid plaque and that miR155 positively correlated with IL-6, IL-1β,
and MMP-9. We showed that miR155 expression was significantly increased in the
fibrous caps of lesions in symptomatic patients compared to those in asymptomatic patients. We also showed that miR155 expression is increased in
calcified media and its expression levels positively correlates with osteogenic
genes, which are confirmed in cell culture and in vivo animal studies. We found
that miR155 deficiency significantly attenuated VSMCs and aortic calcification
induced by calcification media and reduced osteogenic gene expression.
Compared to wildtype mice, miR155 deficient mice showed a significant decrease
in vascular calcification induced by vitamin D3 (vitD3).
2.2 Material and Methods
Human carotid atherosclerotic specimens
Human carotid artery specimens were collected from symptomatic or a
symptomatic carotid atherosclerotic patients undergoing carotid endarterectomy (n
= 81) with patients' informed consent at Greenville Memorial Hospital (Greenville
health system, Greenville, SC, USA) and Palmetto Hospital (Palmetto Health
System, Columbia, SC, USA). Specimens were sliced transversely into 7 mm
segments. One segment from each specimen was dissected into separate
samples representing normal media, atheroma, underlying diseased media, and
fibrous cap.
Vascular smooth muscle cell isolation and culture
Vascular smooth muscle cells were isolated from wild-type or miR155−/−
mice using collagenase digestion as previously described 116. The isolated cells
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were cultured in DMEM supplemented with 10% fetal bovine serum, penicillinstreptomycin, and 2 mM L-glutamine. Cells passage five were used in all of the
experiments. To induce calcification, cells were cultured in calcification media (2
mM CaCl2, and 2 mM inorganic phosphate) for 7 days. Calcification media was
changed every other day.
RNA extraction, cDNA synthesis, and quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was utilized to measure the
expression levels of human interleukins (IL-6 and IL-1β), matrix metalloproteinase9 (MMP-9), and miR-155, Adiporedoxin (Adrx), and osteogenic genes (OPN, BMP2, RUNX-2, and COL-1) in carotid artery specimens. Total RNA, including miRNAs,
were isolated from cultured VSMCs or human specimens after homogenization in
Qiazol lysis reagent (Qiagen, Maryland, USA) using miRNeasy Mini kit (Qiagen,
Maryland, USA) and reverse transcribed to cDNA using miScript-II Reverse
Transcription Kit (Qiagen, Maryland, USA). qRT-PCR was performed using
miScript SYBR Green PCR Kits (Qiagen, Maryland, USA). Human inflammatory
gene expression was normalized with 18S as endogenous control. miR155
expression was detected according to the manufacturer’s instructions using the
miScript PCR System (Qiagen, Valencia, CA, USA) and miScript Primer Assays
(Qiagen, Maryland, USA). Human miR155 gene expression was normalized to U6
as endogenous control. Gene expression levels are reported as ΔCt values relative
to expression of 18S or U6. ΔCt is the difference in threshold cycle between the
gene of interest and the housekeeping gene (18S or U6) as a control. ΔCt levels
are inversely proportional to the gene expression in the sample (the lower the ΔCt
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level the greater the higher expression of target gene in the sample). Primers used
are listed in table 2.1.
Aortic ring culture
Aortas were dissected from wild-type or miR155−/− mice, cut into small rings,
then cultured in calcification media which was changed every other day. After 7
days, aortic rings were harvested for calcium content quantification and embedded
in optimal cutting temperature (OCT) compound (Sakura Finetek USA, Inc.,
Torrance, CA, USA) for frozen section and Alizarin Red staining for calcium
deposition.
Induction of vascular calcification in mice
Twenty week-old male C57BL/6J mice and miR155−/− mice (n=5 for each
group) were used to induce vascular calcification by administration of Vitamin D3
(VitD3) — Cholecalciferol (Sigma Aldrich, St. Louis, MO, USA). VitD3 was
dissolved in absolute ethanol (5 mg per 40 μL) then diluted to a concentration of
3.75 mg/mL with highly refined olive oil (Sigma Aldrich, St. Louis, MO, USA). Stock
solutions of VitD3 were prepared fresh for each 3-day injection cycle and then
placed in foil wrapped containers and stored at 4°C. The mice were
intraperitoneally injected with a dose of VitD3 (100 μL/30 g body weight, 500000
IU/kg, per day) or vehicle (100 μL olive oil, per day) for 10 days. On the 14th day
after injection, blood and aorta tissues were harvested for further analysis.
Calcium content quantification
After decalcification with 0.6 N HCl at 4 ℃ for 24 hour, the calcium content
from cells and tissues were determined in the HCl supernatants using colorimetric
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assay with calcium assay kit (QuantiChromTM Calcium Assay Kit, BioAssay
Systems, Hayward, CA, USA) according to the manufacturer’s instructions. Briefly,
5 μL of the samples was added to a 96-well plate. 200 μL of working reagent was
added and absorbance was measured at 570 nm using a microplate ELISA reader
(BioTek Instruments, Winooski, VT, USA). After decalcification, cells were washed
three times with PBS and solubilized with 0.1 N NaOH/0.1% SDS. The protein
content was measured with a DCTM Protein Assay kit (Bio-Rad). The calcium
content of VSMCs was then normalized to the protein content, whereas that of the
tissues was normalized to tissue dry weight.
For serum calcium measurement, blood was collected from mice by retroorbital venous plexus puncture, serum obtained via centrifugation at 4000 x g for
20 minutes. Serum calcium concentration was measured using the QuantiChrom
calcium assay kit (BioAssay Systems, Hayward, CA, USA) according to the
manufacturer’s instructions.
Alizarin Red S staining
Slides were hydrated with Xylene/Alcohol and washed three times with tap
water. Slides were stained in 1% Alizarin Red S solution (Sigma Aldrich, St. Louis,
MO, USA) at pH 9.0 for 30 minutes. Next, slides were dehydrated in Acetone for
15 seconds, then in Acetone/Xylene for 15 seconds. Then slides were cleaned in
3 Xylene changes, coversliped and visualized under microscope to detect vascular
calcium deposition.
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Western blot analysis
To obtain the total cell lysates, cells were incubated and lysed for 30
minutes on ice in RIPA buffer (PierceTM, Rockford, IL, USA) supplemented with
protease inhibitor cocktail and phosphatase inhibitors (Sigma, Sigma Aldrich, St.
Louis, MO, USA). Equal amount of total cell proteins (30 µg) were separated by 420% SDS–polyacrylamide gel electrophoresis (Bio-Rad) and transferred onto
nitrocellulose membranes (Millipore Corp., Bedford, MA, USA). After blocking with
5% fat-free milk solution, primary antibodies and HRP-conjugated secondary
antibodies were used to detect the protein of interest. The primary antibodies used
were as follows: anti-RUNX2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
anti-OPN (Bioworld Technology, MN, USA), and anti-GAPDH (GeneTex, Irvine,
CA, USA). Signal was detected using Pierce ECL Western Blotting Substrate
(PierceTM, Rockford, IL, USA) and exposed to X-ray film to obtain optimal results
in the dark room. The density of blots was quantified by Image-Pro Plus 6.0
software. For stripping, membranes were submerged for 30 minutes at 55 – 60°C
in a buffer containing 100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris-HCl,
pH 6.7, and washed three times with PBST.
Statistical analyses
Statistical analysis was performed with Graph-Pad Prism 6.0 software
(Graph-Pad Software Inc, San Diego, CA, USA). Statistical significance was
determined using one-way analysis of variance (ANOVA). The correlations
between expression of inflammatory genes and miR-155 expression were
analyzed by linear regression. For mouse experiments, All measurement data
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were expressed as the mean ± standard error of the mean (SEM). Statistical
differences were determined using a Student’s t-test for two group comparisons
and one-way analysis of variance (ANOVA) for multiple group comparison. Data
were considered statistically significant at *P < 0.05, **P<0.01, and ***P<0.001.
2.3 Results
Increased expression of inflammatory cytokines in human carotid
atherosclerotic lesions
First, we examined the expression levels of IL-6 and IL1-β in human
atherosclerotic carotid artery using qRT-PCR. Atheroma, underlying diseased
media, fibrous cap covering the atheroma, and the surrounding normal media from
human atherosclerotic carotid artery were dissected and total RNA was extracted
for measurement of human IL-6 and IL1-β expression. In agreement with the
growing body of literature that demonstrates the higher expression of inflammatory
cytokines in atherosclerotic plaques114,117,118, our results showed that IL-6 and IL1β mRNA expression levels were significantly increased in human carotid plaques.
The expression of IL-6 (Figure 2.1A and 2.1B) and IL-1β (Figure 2.1C and 2.1D)
in different locations of the lesion — atheroma, underlying diseased media and
fibrous cap were significantly higher compared to surrounding normal carotid
media in atherosclerotic carotid artery for the same patient (p<0.05).
Increased expression of matrix metalloproteinase-9 (MMP-9) in human
carotid atherosclerotic lesions
In addition to the uptake of lipoproteins, macrophages secrete inflammatory
mediators and proteinases such as matrix metalloproteinases (MMPs), which play
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a critical role in atherosclerotic plaque progression22. Collagen, a key component
in the fibrous cap of atherosclerotic plaques, helps maintain the plaque stability.
MMPs degrade collagen, leading to increased plaque instability119. Therefore,
inflammation and MMPs contribute to all phases of atherosclerosis, from initiation
through progression and eventually to the thrombotic complications. MMP-9
represents a novel inflammation marker in coronary artery disease patients and its
expression is found to be increased in advanced lesions in atherosclerotic mouse
models and in progressive carotid atherosclerotic plaques obtained from humans
undergoing carotid endarterectomy, especially in the fibrous cap regions where
macrophages accumulate, implicating MMP-9 and macrophages in plaque
rupture120,121. Our data showed that MMP-9 expression was significantly increased
in atheromatous tissue, diseased media and fibrous caps of human atherosclerotic
carotid plaques compared to the adjacent normal media of the same patient
(Figure 2.1E and 2.1F) (p<0.001).
Increased expression of Adiporedoxin in atheroma tissue of human carotid
atherosclerotic plaques
Adiporedoxin (Adrx) is a redox regulatory protein that is expressed in
adipose tissue and plays a critical role in the adipocyte function and regulates
metabolism by modulating secretion of adiponectin that protect from the
development of diabetes and heart disease122. Adrx has been shown to have antiinflammatory effects by negatively regulating macrophage inflammation 123.
Recently, it has been shown that Adrx was expressed in human vascular
endothelial cells, and its expression significantly induced by oxLDL, IL-1β, and
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TNF-α stimulation124. In this study, we examined expression of Adrx in atheroma
tissue from human carotid atherosclerotic plaques. We found that Adrx expression
was significantly increased in the atheroma compared to normal tissue from the
same carotid arteries (Figure 2.1G) (p<0.05). These results suggest induction of
Adrx expression may serve as an intrinsic anti-atherogenic mechanism which can
be exploited for atherosclerosis treatment.
miR155 expression is up-regulated in human carotid atherosclerotic lesions
miR155 has been shown to enhance macrophage inflammation and proved
to be pro-atherogenic115. Recently, we and others showed that the macrophage
miR155 may be pro-atherogenic115,125. We therefore examined the miR155
expression in different locations of human carotid atherosclerotic plaque and
compared to the normal media in the same arteries. In agreement with these
previous studies, we demonstrated that miR155 expression levels were
significantly up-regulated in the atheroma, underlying diseased media, and fibrous
cap compared to the adjacent normal media (Figure 2.2A and 2.2B)(p<0.05).
Moreover, the expression levels of miR155 were compared in the fibrous caps from
a-symptomatic (n=69) and symptomatic (n=12) patients. The results showed that
fibrous caps obtained from symptomatic patients were characterized by
significantly higher expression levels of miR155 compared to those from asymptomatic patients (Figure 2.2C) (p=0.0331).
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Expression levels of miR155 positively correlate with the expression of
inflammatory cytokines and MMP-9 in human carotid plaques
To test whether the expression levels of miR155 are correlated with proinflammatory cytokine expression, we analyzed the correlation between miR155
expression and the expression of inflammation markers; IL-1β, IL-6, and MMP-9
using linear regression. Gene expression levels of inflammation markers, IL-6, IL1β as well as MMP-9 in human carotid plaques showed highly significant positive
correlations

with

miR155

expression

levels

(r=0.377,

r=0.238,

r=0.432

respectively, p<0.0001) (Figure 2.3A, 2.3B, and 2.3C) suggesting that increased
miR155 expression is associated with more inflammation and plaque instability in
human carotid atherosclerotic diseases.
miR155 expression is up-regulated in calcified media and positively
correlated with osteogenic genes
Cardiovascular calcification is a major feature of chronic inflammatory
disorders — such as atherosclerosis and calcific aortic valve disease (CAVD) —
that associate with increased mortality and morbidity126. There has been evidence
that specific miRNAs such as miR-125b, miR-133a, miR-29a/b, miR-204, and miR30b/c — play critical roles in the regulation of vascular calcification, in vitro and in
vivo by regulating the trans-differentiation of VSMCs to osteoblast-like cells127–131.
The role of miR155 in vascular calcification has never been studied. In the current
study, we examined the expression levels of miR155 in calcified media and
correlated that with the expression levels of calcification markers. The results
showed that miR155 was highly expressed in calcified media compared to
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adjacent normal non-calcified media, p=0.0356 (Figure 2.4A). Concurrently, we
examined the expression levels of some calcification (osteogenic) genes, such as
Osteopontin (OPN), Bone morphogenetic protein-2 (BMP-2), Runt-related
transcription factor-2 (RUNX-2), and Collagen Type I Alpha 1 (COL-1). The
expression levels of these genes were significantly up-regulated in calcified media
compared to adjacent non-calcific media, p<0.05 and p<0.01 (Figures 2.4B, 2.4C
2.4D and 2.4E). Next, we analyzed the correlation between expression of miR155
and osteogenic genes. We plotted the correlation of miR155 levels and OPN,
BMP-2, or RUNX-2 levels, showing a clear positive correlation between expression
levels of miR155 with OPN and RUNX-2 expression levels (r=0.446, r=0.322
respectively) (Figure 2.4F). Thus, miR155 seems to influence plaque stability by
influencing the expression levels of osteogenic genes, and thus the grade of
calcification.
miR155 deficiency attenuates VSMCs calcification in vitro
To further study the role of miR155 in vascular calcification and to confirm
the data obtained using human samples, mouse VSMCs were isolated from aorta
of wild-type or miR155−/− mice, cultured in DMEM media supplemented with 5%
FBS, penicillin/streptomycin, and treated with calcification media containing 2 mM
CaCl2 and 2 mM of inorganic phosphate (Pi) to induce calcification. Calcification
media was changed every other day. After seven days, cells were collected,
cellular calcium content was measured. miR155−/− VSMCs showed a significant
decrease in calcium deposition compared to wild-type VSMCs (Figure 2.5A). Then
cells were lysed in Trizol for mRNA extraction. The mRNA expression levels of
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osteogenic genes including BMP-2, RUNX-2, OPN and OCN were detected. The
results showed that the expression of these genes was significantly increased after
calcification media treatment and that the miR155−/− VSMCs had a lower
expression than the wild-type VSMCs, p-value<0.05 (Figure 2.5B). This result
indicated that miR155 deficiency significantly reduced expression of osteogenic
genes in calcified VSMCs. Furthermore, we measured the protein levels of RUNX2 and OPN. The results showed that miR155 deficiency significantly reduced
protein expression levels of RUNX-2 and OPN (Figure 2.5C). These data indicated
that miR155 deficiency attenuated VSMCs calcification by reducing expression of
osteogenic genes.
miR155 deficiency attenuates aortic calcification ex vivo and in vivo
The effect of miR155 on vascular calcification was further assessed ex vivo
and in vivo. The aortas were dissected from miR155−/− or wild-type mice, cut into
rings, and cultured in calcification media. Also, aortas from mice injected with vitD3
were dissected and cut into small rings. The degree of calcification was determined
using alizarin-red staining and tissue calcium content was detected using
colorimetric assays with calcium assay kit. The results demonstrated that miR155
deficiency reduced calcium tissue content and calcium deposition in the calcified
cultured aortic ring (Figures 2.6A and 2.6B) and aortic ring from vitD3 injected mice
(Figures 2.6C and 2.6D). We also measured serum calcium concentration after
vitD3 injection. Interestingly, miR155−/− mice displayed higher serum calcium than
wild-type mice p-value<0.05 (Figure 2.6E). Collectively, these data indicated that
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miR155 deficiency reduced aortic calcification ex vivo and in the aorta of vitD3
injected mice.
2.4 Discussion
Inflammation plays a significant role in all stages of atherosclerosis. The
cytokines secreted by innate and adaptive immune cells regulate the inflammatory
response in atherosclerosis22,31. The expression of inflammatory cytokines in
mouse models of atherosclerosis has been extensively studied. A previous study
found that the expression of the pro-inflammatory cytokines in apoE−/− mice after
4 weeks of high fat diet was significantly increased132. The expression levels of
several pro-inflammatory cytokines in the atherosclerotic plaques were studied
and reported from the mid-1980s mainly in human carotid endarterectomy
specimens112. Better understanding of cytokine gene expression is important for
successful development of therapeutic approaches that decrease the inflammatory
response. Inhibiting cytokine-induced inflammation and promoting the antiinflammatory cytokine response represent potential therapeutic approaches for the
prevention of disease development and progression. Currently available therapies
against atherosclerosis are mainly lipid modulators. While lipid lowering drugs are
successful at reducing the risk of death result from cardiovascular diseases, there
is a need for new therapies that directly target the inflammation to further attenuate
atherosclerosis and improve cardiovascular outcome133.
The expression of inflammation markers in different locations in the human
carotid plaque has not been addressed. In our study we examined the mRNA
expression levels of some inflammation markers in human carotid atherosclerotic
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arteries obtained from patients undergoing carotid endarterectomy. The
specimens were dissected into atheroma, underlying diseased media, fibrous cap,
and the surrounding non-diseased media. The expression levels of inflammation
markers (such as IL-6, IL-1β, MMP-9, miR155, and Adiporedoxin) and calcification
markers (such as OPN, RUNX-2, BMP-2, and COL-1) were measured. IL-6, a proinflammatory cytokine mainly expressed by activated macrophages and VSMCs,
was significantly higher in atheroma, diseased media, and in the fibrous cap
compared to the normal non-diseased media. Similarly, expression of proinflammatory cytokine IL-1β was significantly higher in atheroma, diseased media,
and in the fibrous cap compared to the normal non-diseased media. The
expression level of MMP-9 was higher in atheroma, diseased media, and in the
fibrous cap compared to the normal non-diseased media. Furthermore, the
expression level of miR155, a recently reported pro-inflammatory and proatherogenic microRNA, was significantly up-regulated in the atheroma, diseased
media, and fibrous cap compared to the normal media. Increased expression of
these mRNAs in different locations in human carotid atherosclerotic plaque
suggests they may play a role in atherosclerotic plaque progression. Furthermore,
when we analyzed the expression levels of miR155 in the fibrous caps in
symptomatic patients compared to asymptomatic patients, we found that the
expression levels of miR155 in fibrous cap were significantly higher in symptomatic
compared to those in asymptomatic patients. This might suggest the important role
of miR155 in modulating plaque stability and clinical manifestation of plaque
rupture. The expression of miR155 and calcification markers — such as OPN,
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RUNX-2, Col-1, and BMP-2 in calcified media were also analyzed. The results
showed that miR155 was up-regulated in calcified media occurred concomitant
with increased expression levels of calcification markers, suggesting miR155
might be involved in vascular calcification. Moreover, we showed a positive
correlation between miR155 expression level and osteogenic gene expression
levels. We also used in vitro, ex vivo, and in vivo experiments to determine the
effect of miR155 deficiency on vascular calcification. The results showed that
miR155 deficiency attenuated vascular calcification in VSMCs after calcification
media treatment as well as decreased aortic calcification in vitD3 injected mice.
Furthermore, the expression levels of osteogenic genes in miR155−/− VSMCs after
treatment with calcification media were significantly reduced compared to wild-type
VSMCs. These results were in agreement with the data obtained from human
samples as the increased miR155 expression levels in calcified media occurred
concomitant with increased expression levels of osteogenic genes. Collectively,
these data indicated that miR155 plays a critical role in VSMCs calcification by
increasing expression of osteogenic genes, and inhibiting miR155 may represent
a novel approach to reduce vascular calcification. Inhibition of miR-155 by
antagomiR-155 may provide new therapeutic approach for the prevention and
treatment of vascular calcification caused by a variety of diseases. Investigating
the role of miRNAs in VSMCs calcification will lead to a better understanding of
the mechanisms and to developing drugs directed against specific gene targets for
the treatment of cardiovascular diseases associated with vascular calcification.
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Table 2. 1 Primers that were used for qRT-PCR in this study
Primers

Forward (5’  3’)

Reverse (5’  3’)

18s

CGCGGTTCTATTTTGTTGGT

AGTCGGCATCGTTTATGGTC

hIL-6

TACCCCCAGGAGAAGATTCC

TTTTCTGCCAGTGCCTCTTT

hIL-1β

GGGCCTCAAGGAAAAGAATC

TTCTGCTTGAGAGGTGCTGA

hMMP-9

GATGACGAGTTGTGGTCCCT

GCCTTGGAAGATGAATGGAA

hOPN

CTCCATTGACTCGAACGACTC CAGGTCTGCGAAACTTCTTAG
AT

hRUNX2 TGGTTACTGTCATGGCGGGTA TCTCAGATCGTTGAACCTTGC
TA
hBMP2

ACCCGCTGTCTTCTAGCGT

TTTCAGGCCGAACATGCTGAG

hCOL-1

GAGGGCCAAGACGAAGACAT

CAGATCACGTCATCGCACAAC

C
mBMP2

GGGACCCGCTGTCTTCTAGT

TCAACTCAAATTCGCTGAGGA
C

mRUNX

GACTGTGGTTACCGTCATGG

2

C

GA

mOCN

CTGACCTCACAGATCCCAAG

TGGTCTGATAGCTCGTCACAA

C

G

AGCAAGAAACTCTTCCAAGC

GTGAGATTCGTCAGATTCATC

AA

CG

mOPN
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ACTTGGTTTTTCATAACAGCG
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Figure 2. 1 Increased expression of inflammation markers in human carotid
atherosclerotic atheroma
Carotid artery plaque samples of patients undergoing carotid endarterectomy were
collected. mRNA was isolated from tissue extracts and mRNA transcripts of genes
of interest were measured by qRT-PCR. Results were represented as ΔCt values
after being normalized to the expression of 18s rRNA. ΔCt is the difference in
threshold cycle between the gene of interest and the housekeeping gene (18s
rRNA). ΔCt levels are inversely proportional to the gene expression levels (the
lower the ΔCt level, the higher expression of target gene). (A, B) IL-6 mRNA, (C,
D) IL-1β mRNA, (E, F) MMP-9, and (G) Adrx mRNA in different locations for the
same patients were detected. Each line connects data from a same patient
(*p<0.05, **p<0.01, ***p<0.001)
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Figure 2. 2 Increased expression of miR155 in human carotid atherosclerotic
plaques
Carotid artery plaque samples of patients undergoing a carotid endarterectomy
were collected. mRNA was isolated from tissue. miR155 mRNA levels were
measured using qRT-PCR. Results were represented as ΔCt values after being
normalized to the expression of U6. ΔCt is the difference in threshold cycle
between miR155 and U6. (A, B) Expression levels of miR155 were significantly
increased in atheroma, diseased media, and fibrous cap from human carotid
lesions, compared to those in the normal media. Each line connects data from a
same patient. (*p<0.05, **p<0.01, ***p<0.001). (C) Expression of miR155 in fibrous
cap of carotid atherosclerotic plaques is higher in symptomatic than asymptomatic
patients. (*p=0.033).
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Figure 2. 3 Expression levels of miR155 correlate with the levels of
inflammatory cytokines and MMP-9 in human carotid artery atheroma
Correlation between miR155 expression and pro-inflammatory cytokines IL6 (A),
IL1β (B), and miR155 expression and MMP-9 expression (C) using linear
regression.

38

Figure 2. 4 The expression of miR155 and calcification gene in human
atherosclerotic carotid artery
(A) The expression level of miR155 in human atherosclerotic carotid artery was
assessed by qRT-PCR (n=6 for each group). Results were represented as ΔCt
values after being normalized to the expression of U6. (B, C, D, and E) the
expression levels of osteogenic genes including OPN, COL-1, BMP-2, and RUNX2 in human atherosclerotic carotid artery were assessed by qRT-PCR. Results
were presented as ΔCt values after being normalized to the expression of 18s
rRNA. Each line connects data from a same patient. (n=5 for each group). (F, G)
Correlation between miR155 expression and osteogenic markers (OPN and
RUNX2) using linear regression. *P<0.05, **P<0.01. NM: Normal media; CM:
Calcification media
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Figure 2. 5 miR155 deficiency attenuates calcification in vascular smooth
muscle cells
(A) Calcium content of VSMCs was measured using colorimetric assay with a
calcium assay kit. The expression levels of calcification genes; BMP-2, RUNX-2,
OPN and OCN in VSMCs after treatment with calcification media were detected
by qRT-PCR. (C) Protein levels of RUNX2 and OPN were assessed by western
blotting. *p<0.05
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Figure 2. 6 miR155 deficiency attenuates aortic calcification in vivo and ex
vivo
(A) Calcium deposition in cultured aortic rings from wild-type or miR155−/− mice
was detected by alizarin Red staining. (B) Quantification of calcium content in the
aortic rings using colorimetric assays with calcium assay kit. (C) Calcium
deposition in the aortas of wild-type or miR155−/− mice injected with VitD3 was
determined by Alizarin Red staining. (n=5 for each group). (D) Quantification of
aortic calcium content. (E) Serum calcium concentration was measured by
colorimetric assay using a calcium assay kit. Scale bar, 500 μm. *P<0.05,
**P<0.01.
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Chapter III
The role of Tristetraprolin (TTP) in inflammation and atherosclerosis
3.1 Background
Tristetraprolin (TTP) — also known as ZFP36 (zinc finger protein of 36
kDa)134, Nup 475135, TIS11136, or G0S24137 — is member of a small family of
mRNA-binding proteins containing a tandem Cys-Cys-Cys-His (CCCH) zinc finger
(TZF) domain. The initial description of TTP was in 1990 in mouse 3T3-L1
fibroblasts stimulated with insulin and serum138. This protein is encoded by the
immediate – early response gene called Zinc Finger Protein 36 (ZFP36)139. It is
highly expressed in immune organs in a variety of cell types including monocytes
and macrophages138. Normally, TTP protein levels are low and the protein is
primarily localized in the nucleus of quiescent cells. However, mitogenic
stimulation of cells induces TTP expression and promotes rapid translocation from
the nucleus into the cytoplasm140. Through the TZF domains, TTP can binds
directly to the adenosine-uridine (AU)-rich elements (AREs) in the 3’ untranslated
region (3′-UTRs) of their target mRNAs removing its poly(A) tail; in a process
known as ‘deadenylation’— the rate-limiting step in mRNA decay resulting in
suppression of translation, destabilization and subsequently degradation of the
mRNA transcript through the recruitment of deadenylases or exonucleases 141,142.
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TTP acts at the post-transcriptional level to inhibit the expression of a number of
pro-inflammatory cytokine/chemokines and growth factors. The most apparent
physiological targets of TTP are the mRNAs encoding TNF-α143–145, granulocytemacrophage colony-stimulating factor (GM-CSF)146, Interleukin-2 (IL-2)147,
interleukin-3 (IL-3)148, Interleukin-10 (IL-10)149, Interleukin-12 (IL-12)150, and
Interferon-γ (IFN-γ)151. The role of TTP as an mRNA destabilizing protein initially
comes from the characterization of TTP knockout mice, which appeared normal
and healthy at birth, but after few weeks displayed a complex inflammatory
syndrome manifested by growth retardation, erosive poly-articular arthritis,
conjunctivitis, dermatitis, myeloid hyperplasia, splenomegaly, kidney lesions and
autoimmunity152. This inflammatory phenotype was due to excess production of
the potent pro-inflammatory cytokine, TNF-α145. Furthermore, macrophages
isolated from the TTP knockout mice and stimulated with lipopolysaccharide (LPS)
showed a significant increase in TNF-α mRNA and protein levels due to
stabilization of TNF-α mRNA145,153. The inflammatory phenotype of TTP knockout
mice was significantly attenuated by injecting the mice, soon after birth, with antiTNF-α antibodies or by breeding with TNF-α receptor deficient mice143,154.
To determine whether the excess TNF-α which causes the TTP deficiency
inflammatory phenotype is produced by myeloid cells, myeloid-specific TTP
deficient mice have been generated. Results revealed that mice with myeloidspecific TTP deficiency appeared normal under laboratory conditions. However,
when these mice were challenged with low-dose LPS, they developed severe
endotoxic shock associated with increasing serum TNF-α levels compared to the
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control mice. These studies demonstrated that myeloid cell-specific TTP deficiency
did not completely phenocopy whole-body TTP deficiency in mice under normal
laboratory conditions suggesting that other cell types were involved in the
pathogenesis of the TTP deficiency syndrome155,156. Bone marrow transplantation
has been used to determine if it could transfer the inflammatory phenotype of TTP
knockout mice to recipient mice. Recombination activating gene-2 knockout (RAG2−/−) mice transplanted with TTP deficient bone marrow cells reproduce the TTP
deficiency inflammatory syndrome, which may indicate that hematopoietic cells
play a significant role in excess production of TNF-α that leads to the pathology
reported in TTP knockout mice153. Recently, it has been shown that TTP is a potent
modulator of TNF-α secretion from dendritic cells after LPS stimulation157,158.
TTP has been shown to be highly expressed in the vascular endothelium of
atherosclerotic mice but not in the vascular endothelium of healthy mice. The antiinflammatory effects of endothelial cell TTP might post it as a potential therapeutic
target for the prevention and treatment of atherosclerosis159.
Hematopoietic cells are crucial players in the inflammatory reactions driving
atherosclerosis. In this study, we transplant TTP deficient bone marrow cells into
LDLR−/− mice to examine the effect of hematopoietic TTP deficiency on
inflammation and atherosclerotic lesion development. We investigated whether
bone marrow transplantation transfers the inflammatory phenotype of TTP
knockout and determine its role in atherosclerosis development in LDLR−/− mice.
We first transplanted bone marrow cells from either TTP deficient or wild type mice
into LDLR−/− mice after lethal irradiation, and fed a western diet for 12 weeks to
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induce atherosclerosis. We demonstrate that TTP deficiency in bone marrow cells
transferred the phenotype of TTP deficiency including systemic and multi-organ
inflammation. Surprisingly, we found that TTP deficiency in bone marrow cells did
not affect atherosclerosis development. Unexpectedly, TTP deficiency in bone
marrow cells dramatically reduced plasma lipid and hepatic lipid accumulation
(hepatic steatosis). Increased inflammation and attenuated hyperlipidemia offset
each other leading to unchanged atherosclerosis in LDLR−/− mice.
To

define

the

role

of

macrophage-specific

TTP

deficiency

on

atherosclerosis, LDLR−/− mice were lethally irradiated and reconstituted with either
macrophage-specific TTP deficient bone marrow cells or WT bone marrow cells.
Four weeks after bone marrow transplantation, mice were fed a western diet for 9
weeks. This study reveals that macrophage-specific TTP deficiency did not mimic
the inflammatory phenotype of whole myeloid cell TTP deficiency in mice. In
addition, these mice had comparable lesion size in the aorta and aortic root.
Interestingly, macrophage infiltration and lipid deposition in the aortic root were
reduced in macrophage-specific TTP deficient mice, which might be due to efficient
removal by healthy macrophages in early atherosclerosis.
3.2 Material and Methods
Human carotid atherosclerotic specimens
Human carotid artery samples were collected as described in chapter 2.
Mice
Six to eight week-old female LDLR−/− mice were obtained from Jackson
Laboratories (Bar Harbor, MA, USA). Mice were maintained in pathogen-free

46

conditions at the University of South Carolina according to National Institutes of
Health (NIH) guidelines. Animal care and experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of South
Carolina.
Bone Marrow Transplantation (BMT) and atherosclerosis induction in mice
Bone marrow transplantation was performed as previously described 160.
Briefly, bone marrow cells from donor WT or TTP deficient mice were harvested
from cleaned femurs and tibias by flushing with sterile RPMI-1640 media
(Invitrogen Life Technologies, Grand Island, NY, USA). The cell suspension was
centrifuged at 300 x g for 5 minutes and re-suspended in cold phosphate buffer
saline (PBS). One week before and two weeks after BMT, recipient mice (LDLR−/−
mice) were given autoclaved antibiotic water supplemented with 100 mg/L
neomycin and 500,000 U/L polymyxin B sulfate. Early morning, all recipient mice
were lethally irradiated (900 rad) using a cesium gamma source. Six hours after
irradiation, mice were injected in the retro-orbital venous plexus with nucleated
bone marrow cell (5 X 106 in 200 µL PBS). After BMT, mice were observed for any
signs of bone marrow transplant rejection. To confirm the success of total body
irradiation, one mouse did not transplanted with bone marrow cells. This mouse
died exactly after 2 weeks of total body irradiation. After four weeks recovery, the
resulting chimeric mice were fed a western diet for 12 weeks to induce
atherosclerosis (Figure 3.1A). In order to assess the effect of bone marrow TTP
deficiency in macrophages on atherosclerosis development, lethally irradiated
LDLR−/− mice were reconstituted with macrophage-specific TTP deficient bone
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marrow cells or control (WT) bone marrow cells. Four weeks later, mice were put
on western diet for 9 weeks (Figure 3.1B). During the western diet period, body
weight and food intake were measured weekly. At the experimental endpoint, mice
were euthanized by isoflurane and venous blood from the eyes was collected.
Tissues including: heart, aorta, liver, lung, and spleen were collected and
analyzed.
Peritoneal macrophage isolation and culture
Standard techniques were used to isolate thioglycollate-elicited peritoneal
macrophages. Briefly, mice were injected intraperitoneally (i.p.) with 3 mL of 3%
(w/v) sterile thioglycollate (BD Biosciences Clontech; Palo Alto CA, USA). After 3
days, peritoneal macrophages were collected by washing the peritoneal cavity with
10 mL of cold PBS twice. The cells were centrifuged at 300 x g for 5 minutes and
re-suspended in high-glucose Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum
(FBS), a combination of penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO,
USA), and 50 μM of β-mercaptoethanol. Two million cells/well were cultured in a
12-well plate. Two hours later, cells were washed with PBS to remove the nonadherent cells, and the adherent macrophages cultured in serum free media (SFM)
overnight at 37⁰C and 5% CO2. Macrophages were stimulated with LPS (50 ng/mL,
Sigma-Aldrich) for 6 hours under the same conditions. Treated cells were lysed
with Trizol reagent (Invitrogen, Grand Island, NY, USA) for mRNA extraction.
Expressions of pro-inflammatory cytokines; TNF-α and IL-6 expression were
detected by qRT-PCR.
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VetScan hematology analysis
Blood was drawn into heparinized tubes by retro-orbital puncture. Blood
samples were run on the VetScan HMT hematology analyzer (Abaxis, Union City,
CA, USA). The following parameters were measured: total red blood cells (RBC),
hemoglobin, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), hematocrit (Hct), platelet number, mean platelet volume
(MPV), platelet distribution width (PDW), total white blood cells (WBC),
lymphocytes, mean cell volume (MCV), and red cell distribution width (RDW).
Blood Glucose Measurement
Blood glucose concentration was measured using OneTouch Ultra Blood
Glucose Monitoring System (LifeScan, Inc., Milpitas, CA, USA) following the
manufacturer’s instructions.
Serum Lipid and Lipoprotein Analysis
Total serum cholesterol and triglycerides were determined using enzymatic
colorimetric assays with Cholesterol Reagent and Triglycerides GPO reagent kits
(Raichem; San Diego, CA, USA) at the indicated time points, and analyzed by SoftMax Pro5 software (Molecular Devices, Sunnyvale CA, USA). In brief, mice were
anesthetized with isoflurane, blood was collected by retro-orbital venous plexus
puncture, plasma obtained via centrifugation at 4000 x g for 20 minutes. Serum
was diluted 1:100 in sterile water, 100 µL was loaded on the microplate well and
100 µL of freshly prepared cholesterol and triglyceride reagent were added to the
wells. The plates were incubated 10 minutes at 37⁰C and the absorbance was
measured at 540 nm. Serum lipoproteins were measured using a fast performance
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liquid chromatography (FPLC) system (AKTA purifier, GE Healthcare Biosciences,
Pittsburgh, PA, USA) equipped with a Superose 6 10/300 GL column (GE
Healthcare). Pooled mouse serum (100 µL) was loaded onto the column, and
eluted at a constant flow rate of 0.5 mL/min with 1 mM sodium EDTA and 0.15 M
NaCI. Fractions of 0.5 mL were collected and cholesterol concentration from each
fraction was measured.
Total RNA extraction, cDNA synthesis, and quantitative Real-Time PCR
Total RNAs were extracted from liver tissues and cultured peritoneal
macrophages incubated in SFM with or without LPS stimulation using Trizol
reagent (Invitrogen, Grand Island, NY, USA) following the manufacturer’s
instructions. One microgram of isolated RNA of each sample was reverse
transcribed into complementary DNA (cDNA) in 20 μL reactions using iScriptTM
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed on a
Bio-Rad CFX96 system using iQ™ SYBR® Green Supermix (Bio-Rad) according
to the manufacturer’s instructions. The relative amount of target mRNA was
calculated using the 2(-ΔΔCt) method by normalizing target mRNA Ct values to those
of housekeeping gene, 18S rRNA expression. PCR thermal cycling conditions
were 3 minutes at 95°C, and 40 cycles of 15 s at 95°C and 58 s at 60°C. Samples
were run in triplicate. Primers used are listed in table 3.1
Flow cytometry analysis
The spleen was removed from freshly euthanized mice and smashed in 10
mL RPMI-1640 medium supplemented with 10% FBS using Stomacher® 80
Biomaster (Seward Laboratory Systems Inc., Port St. Lucie, FL, USA). To obtain
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single cell suspensions, tissues were passed through a 70 µM cell strainer (Life
Sciences, Tewksbury, MA, USA). After red blood cell lysis, cells were stained for
30 minutes on ice in dark with anti-CD19 mAb, anti-CD3 PE mAb, anti-CD4 FITC
mAb, anti-CD8a FITC mAb, anti-FOXP3 mAb, anti-ly6C FITC mAb, anti-CD11b
PE mAb, anti-ly6G FITC mAb, and anti F4/80 FITC mAb (eBioscienceTM,
Invitrogen, Grand Island, NY, USA) in staining buffer. Stained cells were acquired
on a Cytomics FC 500 flow cytometer and CXP software version 2.2 (Beckman
Coulter, Brea, CA, USA). Data were collected for 10,000 live events per sample.
Enzyme-linked immunosorbent assay (ELISA)
ELISA assays were performed per the manufacturer’s protocol. Briefly,
blood was collected and centrifuged at 4,000 x g for 20 minute. Serum layer was
removed and diluted 1:5. 96-well ELISA plates were coated with 100 µL of TNF-α
capture antibody (2 µg/mL) and incubated overnight at 4°C. The cells were
incubated with 300 µL of blocking solution (1% BSA, 5% sucrose, and 0.05%
NaN3) for 1 hour at room temperature. Next, 100 µL of each sample were loaded
to each well and incubated for 2 hour at room temperature. After washing three
times, the plates were incubated with biotinylated anti-mouse TNF-α (250 ng/mL),
1 µg/mL horseradish peroxidase streptavidin and substrate solution. The reaction
was stopped by adding 50 µL of 1M H2SO4 solution. Recombinant mouse TNF-α
was used to generate a linear standard curve. Optical density was determined with
a SpectraMax M5 microplate reader at 450 nm (Molecular Devices). All samples
were tested in triplicate.
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Bioplex analysis of serum cytokine/chemokines
Serum levels of 23 cytokine/chemokines from mice were measured using a
Bio-Plex ProTM Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA, USA) on
a Bio-Plex system following the manufacturer’s instructions.
Quantification of atherosclerosis
At the experimental endpoint, all mice were euthanized and the vasculature
was perfused with cold phosphate buffer solution (PBS). The aorta from arch to
bifurcation was fixed in 10% neutral buffered formalin. Then, it was opened
longitudinally, pinned onto black wax plates, and stained with Sudan‐IV (Sigma‐
Aldrich, St. Louis, MO, USA) for aortic enface analysis. Aortic lesion areas were
quantified and analyzed by ImageJ software. The aortic root was isolated and
embedded in Optimal Cutting Temperature (OCT; Tissue-tek) compound (Sakura
Finetek USA, Inc., Torrance, CA, USA) in a plastic mold, stored at - 20 ⁰C. Ten‐
micrometer‐thick cryosections were cut from the proximal 1 mm of the aortic root.
Aortic root sections were assessed for atherosclerotic plaque size with
Hematoxylin and Eosin (H&E) staining method. To analyze the accumulation of
macrophages in the atherosclerotic plaque, Moma-2 (Abcam, Cambridge, MA,
USA) staining was performed. Sections were fixed in acetone for 20 minutes at
room temperature, rinsed with PBS, followed by block in immunostain blocker
solution, and then rinsed with PBS again. The endogenous peroxidase activity was
blocked with 3% hydrogen peroxide. Sections were blocked for non-specific
staining with 5% normal goat serum for 30 minutes at room temperature followed
by incubation with the primary antibody (Moma-2, 1:400 dilution) at 4°C overnight.
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After washing with PBS three times, the biotinylated goat anti-rabbit IgG (Vector
Laboratories,

Burlingame,

CA)

was

used

as

the

secondary antibody.

Immunoreactivity was amplified using the Vectastain ABC kit (Vector
Laboratories), and signal was enhanced by peroxidase enhancer (GeneTex,
Irvine, CA; USA) and reacted with the substrate from AEC Chromogen/FRP
substrate kit (GeneTex Irvine, CA; USA). Nuclei and cytoplasm were
counterstained with haematoxylin for 1 min. Finally, sections washed with
deionized water and air-dry before getting covered with coverslips. Macrophage
infiltration was analyzed via microscope. Inflammatory cell infiltration was
expressed as Moma-2 positive area. Oil red O staining was performed to detect
lipid content in atherosclerotic plaques. Slides placed in oil red O (ORO; Sigma‐
Aldrich) working solution (0.5% in 100% propylene glycol) for 4 hours at room
temperature. Differentiate slides in 85% aqueous propylene glycol three times for
1 minute. Then slides rinsed with deionized water for 2 minutes. Sections were
stained with aqueous hematoxylin (GeneTex, Irvine, CA; USA) for 20 seconds.
Slides washed with deionized water and air-dry. Sections were covered with cover
glasses and analyzed under a microscope. Plaque collagen content was analyzed
using Masson's trichrome staining. Slides were fixed in Bouin’s fluid for 1 hour at
60 °C, washed with water, and then placed in Working Weigert’s Iron Hematoxylin
Stain for 10 minutes. Section were stained with Biebrich Scarlet-acid Fuchsin
solution for 15 minutes and rinsed in distilled water. Next, sections were placed in
Phosphotungstic-Phosphomolybdic Acid solution for 10 minutes, then placed in
Aniline blue for 5 minutes followed by 1% Acetic Acid solution for 3 minutes. Finally,
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slides were dehydrated and cleared through 95% ethanol, 100% ethanol, and
xylenes, 2 changes each, mounted with permount, and coversliped. All images
were recorded with a Nikon E600 Wide field Epifluorescence microscope and
Micropublisher digital camera with Q-imaging software. Plaque size, lipid content,
collagen percentage, and macrophage cell content were quantified by
computerized image Pro-Plus.
Histological analysis
Tissue samples (Liver, lung, kidney and spleen) were fixed in 10% neutral
buffered formalin. H&E staining and microscopy were implemented to detect
infiltrating inflammatory cells. All tissue sections were visualized with a Nikon E
600 microscope.
Microarray analysis
For microarray analysis, liver tissue was lysed with Qiazol, and total RNA
was extracted using RNeasy Mini kit (Qiagen, Germantown, MD, USA). RNA
quality and quantity analysis were determined using Agilent 2100 Bioanalyzer. All
RNA samples had an RNA integrity number (RIN) of 9.2 or higher. The RNA was
amplified and labeled with the Agilent Low Input Quick Amp labeling kit according
to the instructions of the manufacturer. Labeled RNA was then purified using the
Qiagen RNeasy mini kit. mRNA contained in 200 ng of total RNA was converted
into cDNA using a poly-dT primer that also contained the T7 RNA polymerase
promoter sequence. Subsequently, T7 RNA polymerase was added to cDNA
samples to amplify the original mRNA molecules and to simultaneously incorporate
cyanine-3 labeled CTP into the amplification product (cRNA). Labeled cRNA
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molecules were purified using Qiagen’s RNeasy Mini Kit (Valencia, CA). After
spectrophotometric assessment of dye incorporation and cRNA yield, samples
were hybridized to Agilent whole mouse genome microarrays 8 × 60,000 using a
gene expression hybridization kit (Agilent) according to the manufacturer’s
recommendation. Microarray analysis was performed using an Agilent DNA
microarray scanner system. After washes, arrays were scanned using a High
Resolution Agilent DNA Microarray Scanner and images saved in TIFF format. A
heat map of genes from relevant pathways identified by Ingenuity pathway analysis
was generated using R function heatmap.2.
Statistical analysis
Data were presented as mean ± standard error of the mean (SEM).
Statistical analysis was performed with Graph-Pad Prism 6.0 software (Graph-Pad
Software Inc, San Diego, CA, USA). Statistical significance was determined by
one-way analysis of variance (ANOVA) for multi-group comparison and Student’s
t test for two-group comparison. Data were considered statistically significant at *P
< 0.05, **P<0.01, and ***P<0.001.
3.3 Results
TTP is up-regulated in human carotid atherosclerotic lesions
We examined the expression levels of TTP in human carotid atherosclerotic
artery using qRT-PCR. Atherosclerotic lesion and the surrounding normal media
from human carotid artery were dissected from patients undergoing carotid
endarterectomy. Total RNA extraction and qRT-PCR analysis were performed to
measure the expression of human TTP mRNA. In agreement with a previous
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study159, we demonstrated that TTP is highly expressed in atheromatous tissue
compared to the adjacent normal media in the carotid atherosclerotic plaques pvalue <0.05 (Figure 3.2).
TTP deficiency in bone marrow-derived cells causes growth retardation, but
did not affect food intake
Five million bone marrow cells from either TTP deficient mice or WT mice
were transplanted into lethally irradiated LDLR−/− mice. After 4 weeks recovery, the
recipient mice were challenged with a western diet for 12 weeks, after which mice
were sacrificed. During western diet period, mouse food intake and body weight
were measured weekly. None of these mice showed any signs or symptoms of
bone marrow transplant rejection. We did not observe significant differences in
food intake between bone marrow TTP deficient mice and control mice (Figure
3.3A). There was, however, a reduction in the mouse body weight with bone
marrow TTP deficiency (Figure 3.3B). This reduction in body weight and cachexia
was the most important characteristic phenotype of TTP knockout mice161.
TTP deficiency in bone marrow-derived cells causes hematological and
Immunological disturbance
Previous studies showed that there is a hematological and immunological
disturbance associated with TTP deficiency161–163. To determine the effect of bone
marrow TTP deficiency on hematological and immunological status of TTP
deficient bone marrow transplanted LDLR−/− mice, we performed Vetscan HMT
analysis of peripheral blood at the experimental endpoint. The results showed an
increase in the number of white blood cells, number and percentage of blood
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monocytes, but these changes did not reach statistical significance, perhaps
because of the relatively small sample number (n=5-6). There was, however, a
significant increase in the number and percentage of neutrophils (P=0.0037,
P=0.0336 respectively) of bone marrow TTP deficient mice compared to the
control mice (Figure 3.4A). Total platelet number, platelet hematocrit were
significantly increased (P=0.0107, P=0.0053 respectively) in bone marrow TTP
deficient mice compared to the control mice (Figure 3.4B). On the other hand, we
did not observe any differences in the red blood cell count, hemoglobin
concentration, hematocrit, mean corpuscular volume, mean corpuscular
hemoglobin, MCHC, and the RDWC between the two groups (Figure 3.4C). Flow
cytometric analysis of the leukocytes population in the spleen showed a significant
decrease in the number and percentage of CD3+/CD4+ T lymphocytes, and a
significant increase in CD11b+/GR1+ myeloid cells, CD11b+/Ly6G+ (neutrophils),
CD11b+/Ly6Chigh

(inflammatory

monocytes).

Whereas,

the

number

and

percentage of CD19+ B lymphocytes, CD3+/CD8a+ T lymphocytes, CD4+/FoxP3+,
CD4+/IL17+, CD11C+, F4/80+, and CD11b+/Ly6Clow were comparable between the
two groups (Figures 3.5A & 3.5B). Even though the spleens of bone marrow TTP
deficient mice were slightly enlarged (Figure 3.5C), the absolute cell numbers were
comparable to those of control mice (Figure 3.5D). These results indicated that the
bone marrow TTP deficiency causes hematological and immunological
disturbance as previously reported in TTP knockout mice 164.
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TTP deficiency in bone marrow-derived cells increases expression of proinflammatory cytokines
A number of pro-inflammatory cytokines produced by macrophages
including, TNF-𝛼 and IL-6, were used to assess the ability of macrophages to
produce cytokines163. These cytokines play a crucial role in the macrophage
response to LPS stimulation. Peritoneal macrophages of bone marrow TTP
deficient mice and WT mice were isolated by washing the peritoneal cavity,
cultured and treated with LPS (50 ng/mL) for 6 hours. The expression of proinflammatory cytokines TNF-α and IL-6 mRNA were measured by qRT-PCR. The
results showed a significantly higher expression of TNF-α mRNA, p-value 0.0071
(Figure 3.6A) and IL-6 mRNA (Figure 3.6B) in TTP deficient macrophages after
stimulation with LPS compared to WT ones. These data indicated that TTP
deficient macrophages had a higher ability to produce TNF-α after LPS stimulation
and confirmed that TNF-α is one of the physiological-targets of TTP165.
TTP deficiency in bone marrow-derived cells causes systemic and multiorgan inflammation
As the TTP knockout mice developed a severe inflammatory phenotype161,
we next evaluated the inflammatory phenotype of bone marrow TTP deficient mice.
Mouse tissues were isolated, fixed, and stained with H&E. The histological analysis
of these mice showed a wide degree of variation, where some of them had severe
abnormal findings, while others had a mild abnormal finding typical of whole body
TTP knockout. The bone marrow TTP deficient mice had no difference in liver
weight (Figure 3.6C), however, H&E staining showed a significant inflammatory
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cell infiltration and foci of liver necrosis around the central vein (Figure 3.6D). In
the lung of bone marrow TTP deficient mice, there was a great deal of inflammatory
cell infiltration surrounding the vasculature, indicating the movement and migration
of the inflammatory cells. In addition, these mice exhibit more inflammatory
exudate in the alveolar space compared to the control group (Figure 3.6E). The
spleen showed a loss of the normal organization with no clear demarcation
between the red and the white pulp due to inflammatory infiltration (Figure 3.6F).
To further define the effect of bone marrow TTP deficiency on systemic
inflammation, we performed ELISA assays to detect serum TNF-α levels. The
serum TNF-α concentration was increased in the bone marrow TTP deficient mice
compared to control mice p-value 0.0004, further indicating that these mice have
systemic inflammation (Figure 3.6G).Taken together, these data indicate that bone
marrow TTP deficiency in LDLR−/− mice significantly increased systemic and multiorgan inflammation.
TTP deficiency in bone marrow-derived cells does not affect atherosclerosis
in LDLR−/− mice
In order to assess the effect of bone marrow TTP deficiency on
atherosclerosis, we fed the chimeric mice a western diet for 12 weeks and
quantified atherosclerotic lesion formation and parameters of plaque complexity.
Even though the bone marrow TTP deficient mice have a systemic inflammation,
the bone marrow TTP deficiency did not significantly modify the atherosclerotic
lesion size (Figure 3.7A). Similarly, the lipid contents in the aortic root were found
to be the same (Figure 3.7B); there was no significant difference in the
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macrophage content (Figure 3.7C) and collagen percentage (Figure 3.7D) in bone
marrow TTP deficient compared with the control mice. These results indicated that
the bone marrow TTP deficiency did not result in alteration of atherosclerosis in
LDLR−/− mice.
TTP deficiency in bone marrow-derived cells reduces plasma lipid and
attenuated hepatic steatosis
Atherosclerosis is both a lipid deposition disorder and a chronic
inflammatory disease166. Previous studies have shown that pro-inflammatory
signaling in pre-clinical models does affect lipid metabolism167. Hyperlipidemia is
usually associated with systemic inflammation168. Next, we investigated the effect
of bone marrow TTP deficiency on serum lipid. Serum total cholesterol and
triglyceride levels were measured at the indicated time points. Interestingly, after
8 weeks of western diet the bone marrow TTP deficient mice had dramatically
reduced serum total cholesterol and triglyceride levels compared to the control
mice p-value 0.0001, 0.0006 respectively (Figures 3.8A and 3.8B). In agreement
with 8 weeks western diet, at the experimental endpoint, bone marrow TTP
deficient mice showed a significant reduction in serum cholesterol and triglyceride
p-value 0.0009, 0.0022 respectively (Figures 3.8C and 3.8D). Fast Protein Liquid
Chromatography (FPLC) analyses of serum lipoproteins showed the difference in
very low-density lipoprotein (VLDL), LDL, and high-density lipoprotein (HDL)
cholesterol peaks between bone marrow TTP deficient mice and control mice
(Figures 2.8E and 2.8F). Interestingly, bone marrow TTP deficient mice exhibited
significantly lower VLDL cholesterol levels, whereas no difference was observed
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in LDL and HDL cholesterol. The liver is the most important organ involved in lipid
metabolism169; we measured the liver lipid content of the frozen liver sections using
the Oil-Red-O (ORO) staining and showed that hepatocytes of bone marrow TTP
deficient mice had a dramatically reduced lipid accumulation compared to the
levels in control mice (Figure 3.8G). Additionally, cholesterol excretion in the feces
were significantly decreased in bone marrow TTP deficient mice p-value<0.0001
(Figure 3.8H). We also measured the blood glucose levels and the body
temperature at the end point. No significant differences in these parameters were
detected between the two groups (Figures 3.8I and 3.8J). Collectively, these data
suggest that the bone marrow TTP deficiency in atherogenic LDLR−/− mice
dramatically reduced plasma total cholesterol levels particularly in VLDL fraction,
and hepatic steatosis.
TTP deficiency in bone marrow-derived cells alters expression of liver genes
involved in inflammation and lipid metabolism
To gain further insight into the genes related to hepatic lipid metabolism and
inflammation in bone marrow TTP deficient mice and to further explore the
underlying molecular mechanisms for the above observed phenotype, a
microarray gene analysis was performed on mRNA isolated from liver of bone
marrow TTP deficient mice and control mice. We found that bone marrow TTP
deficiency significantly modulated 236 genes with corrected p-value cut-off:0.05
and an absolute fold change >2.00 (Figure 3.9A). Of the 236 genes, there were 27
genes involved in lipid metabolism, and inflammation that were significantly
changed in bone marrow TTP deficient mice compared to mice with WT bone
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marrow cells (Figure 3.9B). Furthermore, the lipid related genes such as sterol
regulatory element binding transcription factor-1 (SREBF-1), which controls the
expression of enzymes involved in fatty acid and cholesterol biosynthesis 170 were
significantly downregulated whereas the genes involved in modulating immune
response and inflammation such as Serum Amyloid A1 (SAA1), CC chemokine
receptor-2 (CCR2) were highly expressed in the livers of bone marrow TTP
deficient mice.
To confirm the gene expression patterns identified by the microarray
analysis, qRT-PCR experiments for the mRNA expression of selected genes
(SSA1, CCR2, and SREBF1) were performed. Indeed the expression of several
genes from microarray data were validated by qRT-PCR. SREBF1 was
significantly down-regulated in the liver of bone marrow TTP deficient mice;
however, the mRNA expression of the inflammatory CCR2 and SAA1 genes were
significantly upregulated p-value<0.05 (Figure 3.9C).
Taken together, although we did not analyze in detail all of the differentially
expressed genes related to lipid metabolism, our study indicated that many key
genes related to lipid metabolism were influenced by bone marrow TTP deficiency,
suggesting that the bone marrow TTP deficiency could change the expression of
lipid metabolism genes particularly SREBPF1 resulting in decreased lipid
production by the liver and subsequently reduced serum lipid, hepatic steatosis,
and lipid excretion.

62

Effect of macrophage-specific TTP deficiency on inflammation and
atherosclerosis development
Macrophages play a central role in the initial step of atherosclerotic lesion
formation171. To evaluate the contribution of macrophage TTP to atherosclerosis
development in LDLR−/− mice, we utilized bone marrow transplantation studies to
generate a macrophage-specific TTP deficient mouse model. We transplanted
atherosclerosis susceptible six to eight week-old female LDLR−/− mice after lethal
irradiation with bone marrow from either macrophage-specific TTP knockout
(LysM-cre/TTPfl/fl, mac-TTP−/−) or control (TTPfl/fl, WT) mice. After a recovery
period of 4 weeks on regular murine chow diet, the transplanted mice were
challenged with a western diet for 9 weeks to induce atherosclerosis (Figure 3.1B).
Western blot analysis and PCR were utilized to confirm that the reconstitution of
the macrophage-specific TTP deficient bone marrow was efficient indicated by the
lack of expression of TTP in the resident peritoneal macrophages (Figures 3.10A
and 3.10B). During western diet period, mice body weight and food intake were
monitored weekly. Throughout the experiment, macrophage-specific TTP deficient
mice and control mice showed a similar food intake (Figure 3.11A) while the weight
gain slightly reduced in macrophage-specific TTP deficient mice (Figure 3.11B). In
addition, there were no differences in the spleen weight between the two groups
(Figure 3.12A). Flow cytometric analysis of splenocytes showed no difference in
leukocyte population (Figure 3.12B). To further assess the influence of
macrophage-specific TTP deficiency on systemic inflammation, we utilized the BioPlex Assays to measure the levels of cytokine/chemokines in the serum. We found
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that macrophage-specific TTP deficiency significantly increased the plasma levels
interleukin-12 (IL12-P40), one of the known TTP targets (Figure 3.12C). At the
experimental endpoint, we measured serum total cholesterol (Figure 3.13A),
triglyceride (Figure 3.13B) and lipoprotein fractions (Figure 3.13C). Interestingly,
macrophage-specific TTP deficiency had no significant effects on serum
cholesterol and triglyceride as well as lipoprotein fractions. After overnight fasting,
these mice also showed similar blood glucose levels (Figure 3.13D).
To investigate the effect of macrophage-specific TTP deficiency on
atherosclerotic lesion development, en face aortic atherosclerotic lesion and aortic
root lesion sizes were quantified after 9 weeks of western diet. Macrophagespecific TTP deficiency did not significantly affect atherosclerotic lesion size as
compared to the control mice (Figures 3.14A and 3.14B). Interestingly, ORO
staining of the aortic root showed a significant reduction in the lipid accumulation
in macrophage-specific TTP deficient mice p-value 0.009 (Figure 3.14C).
Moreover, the macrophage infiltration in the atherosclerotic lesion was significantly
reduced p-value 0.022 (Figure 3.14D). The plaque stability was also assessed by
using trichrome staining of the aortic root section, and we found that there was no
difference in the collagen percentage with macrophage-specific TTP deficiency
(Figure 3.14E).
3.4 Discussion
TTP is a member of CCCH tandem zinc finger proteins family. It binds via
its tandem zinc finger domain to AU rich elements (AREs) found in 3’ UTR of the
target mRNAs such as that of TNF-α, resulting in deadenylation and destabilization
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of the target mRNAs164,172. TTP has been demonstrated to play a significant role
in controlling inflammation in the vascular endothelial cells159.
Previous studies demonstrated that TTP deficiency resulted in development
of a complex syndrome of myeloid hyperplasia with cachexia, skin lesions, arthritis,
conjunctivitis, kidney lesions, and that treatment with TNF-α antibodies161 or
interbreeding the mice with TNF-R deficient mice 173 could attenuate development
of above inflammatory phenotype in the TTP deficient mice. Transplantation of
TTP deficient hematopoietic cells reproduces the whole body TTP knockout
inflammatory syndrome in RAG-2 deficient mice, indicating that hematopoietic
cells contribute dominantly to the phenotype153. However, the effects of bone
marrow TTP deficiency on atherosclerosis have not been studied. In our study, we
transplanted bone marrow cells from either TTP knockout mice or WT mice into
LDLR−/− mice, and we wanted to test if the bone marrow transplantation of TTP
deficient cells could transfer the inflammatory phenotype of TTP knockout mice
into recipient atherogenic LDLR−/− mice and to examine the impact of bone marrow
TTP deficiency on atherosclerosis development. TTP has anti-inflammatory
properties, and inflammation plays a significant role in the development of
atherosclerosis174; therefore, we expected that the bone marrow TTP deficiency
would increase inflammation and lead to increased atherosclerosis in
hyperlipidemic LDLR−/− mice. First we studied the inflammatory phenotype in bone
marrow TTP deficient mice and found that TTP deficient bone marrow
transplantation into LDLR−/− mice resulted in all aspects of TTP knockout syndrome
including: growth retardation, systemic and multi-organ inflammation, suggesting
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that hematopoietic progenitors are responsible for the development of the
inflammatory syndrome. We then aimed to determine whether bone marrow TTP
deficiency affects atherosclerosis development. A comparable lesion size in the
aortic root was observed between bone marrow TTP deficient mice and control
mice. Plaque composition analysis showed no effects of bone marrow TTP
deficiency on the lipid content or macrophage content either, as well as amount of
collagen. Then we evaluated the effect of bone marrow TTP deficiency on lipid
profile and found that these mice had a significant reduction in plasma lipid and
hepatic steatosis. Increased inflammation and reduced plasma lipid might thus
counteract each other leaving atherosclerosis development unchanged in bone
marrow TTP deficient mice compared to bone marrow WT mice. Previous studies
demonstrated the inflammatory phenotype of TTP knockout mice, and that
transplantation of TTP deficient bone marrow cells into RAG2 deficient mice could
transfer all aspects of TTP deficiency syndrome. We, for the first time, show that
bone marrow TTP deficiency significantly increased inflammation, reduced plasma
lipid, and attenuated hepatic steatosis, but did not affect western diet-induced
atherosclerotic lesion development in LDLR−/− mice. Bone marrow TTP deficient
mice had lower body weight than control mice; these mice also displayed
hematopoietic abnormalities including slightly elevated white blood cell count,
increased absolute number and percentage of neutrophils, increased absolute
number and percentage of blood monocytes. The peripheral red blood cell count,
hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin
were not different between the two groups. However, the platelet count, and
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platelet hematocrit were significantly increased (P=0.0107, P=0.0054 respectively)
in bone marrow TTP deficient mice. Flow cytometric analysis of the leukocyte
population in the spleen revealed that CD3+/CD4+ T cell numbers and percentage
decreased significantly with bone marrow TTP deficiency, whereas the number
and percentage of neutrophils and inflammatory monocytes were increased
significantly in bone marrow TTP deficient mice compared to the control mice. No
difference was observed in the B lymphocytes between the two groups. In addition,
the isolated peritoneal macrophages were cultured and treated with LPS (TLR4
ligand), and shown to have a significantly higher expression of pro-inflammatory
cytokines,

TNF-α

and

IL-6,

indicating

that

TTP

deficiency

increased

responsiveness of macrophages to LPS stimulation. The most striking observed
feature of TTP deficiency is the diffuse multi-organ inflammation161,162. Our data
demonstrated that the bone marrow TTP deficiency results in inflammatory cell
infiltration in multiple organs including liver and lung. The spleen weight of bone
marrow TTP deficient mice was slightly enlarged compared to the control mice. In
addition, microscopically there is a disturbed morphology of the spleen due to a
large inflammatory cell infiltration in bone marrow TTP deficient mice. Those mice
also had increased plasma TNF-α levels. We expected that, with the increase in
inflammation

caused

by

bone

marrow

TTP

deficiency,

more

severe

atherosclerosis would develop in these mice. However, bone marrow TTP
deficiency did not increase atherosclerosis in LDLR−/− mice after 12 weeks of
western diet feeding. Interestingly, the plasma total cholesterol and triglyceride
levels, especially those in the VLDL fractions were significantly reduced in bone
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marrow TTP deficient mice. Additionally, these mice showed significantly
decreased hepatic lipid accumulation (hepatic steatosis) compared to bone
marrow WT mice.
To gain further insight into the genes related to lipid metabolism and
inflammation in the bone marrow TTP deficient mice, and to understand the
underlying molecular mechanism by which bone marrow TTP deficiency reduces
liver lipid production, we performed a microarray analysis to compare the liver gene
expression patterns of these mice. We found that there were 236 genes
significantly changed with bone marrow TTP deficiency; among these there were
27 genes involved in lipid metabolism and inflammation that were significantly up
or down regulated with bone marrow TTP deficiency. Those down-regulated genes
tend to regulate cholesterol and fatty acid metabolism such as SREBF1 and
ABCG8, whereas up-regulated genes were involved in inflammation such as
CCR2, SAA1, and Calgranulin A (S100A8) a biomarker for chronic inflammatory
diseases175. SREBF-1, a key transcription factor regulating lipogenic enzymes170.
To further dissect the role of macrophage TTP in atherosclerosis
development, we transplanted the bone marrow cells from macrophage-specific
TTP knockout mice or WT mice to LDLR−/− mice. After 4 weeks of hematopoietic
reconstitution followed by 9 weeks of western diet, the serum concentration of IL12P(40) was the only cytokine significantly increased in macrophage-specific TTP
deficient mice than the control. Furthermore, no significant change in serum
cholesterol and triglyceride levels were observed with macrophage-specific TTP
deficiency. Finally, the atherosclerotic lesion size in LDLR−/− mice was unchanged.
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However, macrophage-specific TTP deficiency resulted in significant changes in
lesion composition during the initial stages of plaque development. This occurred
through reduction in macrophage infiltration, and lipid content. Overall, our data
demonstrated that loss of macrophage-specific TTP expression in LDLR−/− mice
results in unchanged atherosclerosis indicating that TTP expression in
macrophages does not play an important role in atherogenesis.
In conclusion, our study provides evidence that bone marrow TTP
deficiency in LDLR−/− mice results in significantly increased inflammation and
attenuated hyperlipidemia. The increased systemic inflammation and reduced
serum lipid levels in bone marrow TTP deficient mice offset each other and resulted
in no significant change in the atherosclerosis development in mice. Although it is
unknown if TTP directly acts on lipoprotein metabolism related genes, it is
intriguing to hypothesize that targeting certain components of immune system and
inflammation may have unexpected effects on hepatic lipoprotein metabolism. This
aspect is a subject for further investigation. In addition, our results demonstrate
that macrophage-specific TTP deficiency had less robust effects than whole bone
marrow cell TTP deficiency on inflammation and serum lipid, suggesting TTP
expression in other bone marrow-derived cells contributes more to inflammation
and lipoprotein metabolism.
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Table 3. 1 Primers that were used for qRT-PCR in this study
Primers

Forward (5’  3’)

Reverse (5’  3’)

m18s

CGCGGTTCTATTTTGTTGGT

AGTCGGCATCGTTTATGGTC

hTTP

TACGAGAGCCTCCAGTCGAT

GCGAAGTAGGTGAGGGTGA
C

mTNF-α

CGT CAG CCG ATT TGC TAT CGGACTCCGCAAAGTCTAAG
CT

mIL6

AGTTGCCTTCTTGGGACTGA

TCCACGATTTCCCAGAGAAC

mSREBF

GCCCACAATGCCATTGAGA

GCAAGAAGCGGATGTAGTCG

1
mCCR2

AT
ATTCTCCACACCCTGTTTCG
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GATTCCTGGAAGGTGGTCA

Figure 3. 1 In vivo experimental design, mouse model and bone marrow
transplantation used for assessment of atherosclerosis
(A) six to eight week-old female LDLR−/− mice were provided with autoclaved
antibiotics water containing neomycin (100 mg/L) and polymyxin B sulphate
(60.000 U/L) one week before and two weeks after bone marrow transplantation.
Mice received total body irradiation. Bone marrow cells were isolated from TTP
knockout mice or control mice and 5 x 106 cells injected into LDLR−/− mouse in the
retro-orbital plexus. Four weeks after the BMT, mice were fed a western diet for a
period of 12 weeks, then the mice were sacrificed for atherosclerosis analysis. (B)
six to eight week-old female LDLR−/− mice were provided with autoclaved
antibiotics water one week before and two weeks after BMT. Mice received total
body irradiation. Bone marrow cells were isolated from macrophage-specific TTP
deficient mice or control mice and 5 x 106 cells injected into LDLR−/− mouse. Four
weeks after BMT, mice were fed a western diet for 9 weeks, then the mice were
sacrificed for atherosclerosis analysis.

71

*

ct (hTTP)

25
20
15
10
5
0

or

m

a

lm

ia
ed
t
A

ro
he

m

a

N

Figure 3. 2 TTP expression is increased in human carotid atherosclerotic
lesions
TTP expression in human carotid artery was analyzed by qRT-PCR. Expression
levels of TTP were significantly increased in carotid atherosclerotic lesions
compared to those in the non-lesion carotid medial tissue. Results were
represented as ΔCt values after being normalized to the expression of 18s rRNA.
ΔCt is the difference in threshold cycle between the gene of interest and the
housekeeping gene (18s). Each line connects data from a same patient. (*p<0.05).
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Figure 3. 3 Bone marrow TTP deficiency causes growth retardation, but did
not affect food intake
Six to eight week-old female LDLR−/− mice were transplanted with TTP knockout or
WT bone marrow cells. Four weeks after BMT, mice were fed a western diet for 12
weeks. (A) Food intake and (B) body weight were monitored weekly. The average
daily intake of western diet per mouse was calculated. Data are presented as mean
± SEM.
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Figure 3. 4 Bone marrow TTP deficiency causes hematological disturbance
VetScan hematology analyzer was utilized to measure the following parameters:
(A) white blood cell and white blood cells differential counts in peripheral blood at
the experimental endpoint. (B) Total platelet number, mean platelet volume,
platelet distribution width (PDWc), and the platelet hematocrit. (C) Red blood cell
(RBC) number, hemoglobin (HGB) concentration and hematocrit (HCT), mean
corpuscular volume, mean corpuscular hemoglobin concentration (MCHC), red
cell distribution width (RDWc). All data were presented as the mean ± SEM.
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Figure 3. 5 Bone marrow TTP deficiency causes immunological disturbance
Spleens from bone marrow TTP deficient mice and bone marrow WT mice were
collected at experimental end point. A single cell suspension was made, and the
cells were stained with different antibodies to detect different mouse leukocyte
populations by flow cytometry. (A) Absolute number and (B) percentage of
leukocytes in the spleen. (C) Spleen weight of LDLR−/− mice that received WT or
TTP deficient bone marrow cells. (D) Total spleen cell numbers of LDLR −/− mice
that received WT or TTP deficient bone marrow cells. (*P<0.05; **P<0.01).
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Figure 3. 6 TTP deficiency increased macrophage responses to LPS
stimulation, and bone marrow TTP deficiency resulted in extensive
inflammatory tissue damage and systemic inflammation
Residential peritoneal macrophages were obtained from mice at the experimental
endpoint. The cells were treated with LPS (50 ng/mL) for 6 h. Total mRNA was
extracted for qRT-PCR measurement of the inflammatory cytokine expression (A)
TNF-α, (B) IL-6 (N=3 for each group). (C) Liver weight of LDLR−/− mice received
WT or TTP deficient bone marrow cells. Representative photomicrographs
showing H&E staining in the (D) liver (20x), (E) lung (20x), and (F) spleen (10x) in
wild-type recipient mice (right panels) and TTP deficiency recipient mice (left
panels). (G) Serum TNF-α concentrations of bone marrow TTP deficient mice and
control mice were determined by ELISA. Data were analyzed by Student’s t test.
*p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. 7 Bone marrow TTP deficiency had no impact on atherosclerosis
after 12 weeks of western diet in LDLR−/− mice
To induce atherosclerosis, bone marrow transplanted LDLR−/− mice were fed a
western diet for 12 weeks. The aortic roots were embedded in OCT and frozen at
-20 °C. For analysis of atherosclerosis, 10 µm thick sections were collected. (A)
The aortic root lesion area of the frozen sections was detected by H&E staining
and quantified by Image-ProPlus 6.0. The representative images and quantitative
analysis are shown. (B) Lipid contents in the aortic root lesions were determined
by ORO staining. The representative images and quantitative analysis are shown.
(C) The areas of macrophages in the aortic root lesions were determined by
immunostaining for MOMA-2 (a macrophage marker). The representative images
and quantitative analysis are shown. (D) Collagen content in the aortic root lesions
was determined by masson’s trichrome staining. The representative images and
quantitative analysis are shown.
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Figure 3. 8 Bone marrow TTP deficiency markedly reduced serum lipid
levels and attenuated hepatic steatosis
Mouse serum cholesterol (A) and triglyceride (B) levels were measured after 8
weeks of western diet. Mouse serum cholesterol (C) and triglyceride (D) levels
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were measured at the experimental end point. (E, F) Pooled serum samples from
mice at the experimental endpoint were analyzed for the lipoprotein profile using
FPLC analysis. Cholesterol or triglyceride content in each fraction was determined.
Data represent the mean ±SEM. (G) Representative images and quantification of
ORO stained liver sections. (H) Fecal cholesterol excretion was detected at the
experimental end point. (I) Fasting blood glucose levels of mice at the experimental
end point were measured. (J) Body temperatures at the experimental end point
were measured. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. 9 Bone marrow TTP deficiency alters expression of liver genes
involved in inflammation and lipid metabolism
(A) Heat map showing the expression of 236 genes significantly changed in the
liver of bone marrow TTP deficient mice compared to control mice (2.00 fold
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change cutoff). (B) Heat map of 27 genes involved in inflammation and lipid
metabolism significantly changed with bone marrow TTP deficiency. Color coding
indicates increased gene expression in red, and decreased expression in green.
The columns and rows in the heat maps represent samples and genes,
respectively. (C) Quantitative real-time RT-PCR analysis of liver mRNA was used
to verify the results of selected genes from microarray data.
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Figure 3. 10 Efficiency of macrophage-specific TTP deficiency in the bone
marrow transplantation model
Thioglycollate-elicited peritoneal macrophages were lysed in Trizol reagent for
mRNA isolation and PCR analysis or RIPA buffer for protein isolation and western
blot analysis. Western blot and PCR were utilized to detect TTP protein (A) and
TTP mRNA (B) expression.
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Figure 3. 11 macrophage-specific TTP deficiency did not affect mouse food
intake, but reduced body weight
LDLR−/− mice were transplanted with WT or macrophage-specific TTP deficient
bone marrow cells. Four weeks after bone marrow transplantation, mice were fed
a western diet for 9 weeks. (A) Food intake and (B) body weight were monitored
weekly. The average daily intake of western diet per mouse was calculated. Data
are presented as mean ± SEM.
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Figure 3. 12 Effect of macrophage-specific TTP deficiency on inflammation
(A) Spleen weight of LDLR−/− mice that received WT or macrophage-specific TTP
deficient bone marrow cells at the experimental endpoint. (B) Flow cytometry
analysis of leukocyte population in the spleen. Percentage of each subset of cells
were shown. Data are represented as the mean ± SEM. (C) Serum levels of 23
chemokine/cytokines were measured by Bio-Plex ProTM Mouse Cytokine 23-plex
Assay. Data are presented as the mean ± SEM. *P<0.05.
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Figure 3. 13 Effect of macrophage-specific TTP deficiency on plasma lipid
levels and lipoprotein profile
LDLR−/− mice reconstituted with WT or macrophage-specific TTP deficient bone
marrow cells were fed a western diet for 9 weeks. Blood samples were drawn after
overnight fasting. The concentrations of cholesterol (A) and triglycerides (B) in
serum were determined using enzymatic colorimetric assays. (C) Plasma
lipoproteins profile was determined by FPLC analysis. Fractions represent VLDL,
LDL, and HDL, respectively. (D) Fast blood glucose levels after were determined.

87

Figure 3. 14 Effect of macrophage-specific TTP deficiency on atherosclerosis
(A) Representative image of the aorta stained with Sudan IV and quantification of
the surface area occupied by the lesions. (B) Representative images and
quantitative analysis of atherosclerotic lesion size in the aortic root of WT and
macrophage-specific TTP deficient mice. (C) Representative images and
quantitative analysis of ORO stained aortic root. **p<0.001. (D) Representative
images and quantitative analysis of MOMA2 stained area in the aortic root.
*P<0.05 (E) Representative images and quantitative analysis of collagen content
in the aortic root.
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Chapter IV
The effect of macrophage-specific GP-96 deficiency on inflammation and
atherosclerosis development
4.1 Background
Glycoprotein-96 (GP-96), also known as glucose regulated protein-94
(GRP-94), endoplasmin, or 99-kDa endoplasmic reticulum protein (ERp99), is an
endoplasmic reticulum (ER)-resident chaperone/stress protein176.

GP-96 is

expressed in various cell types, and its expression can be upregulated by
accumulation of misfolded proteins and other stress conditions that leads to
disturbance in the ER functions177,178. Initially, GP-96 was discovered as a protein
strongly induced by glucose starvation in hamster fibroblasts as a major
endoplasmic reticulum calcium-binding protein179. Recently, the role of GP-96 in
innate immunity, inflammation and oncogenesis started to be appreciated180,181.
GP-96 plays a major role in maintaining protein homeostasis by catalyzes
the folding of the newly synthesized proteins such as Toll like receptors (TLRs),
Wnt co-receptor LRP6, insulin-like growth factors, immunoglobulins (Ig), and some
integrins180,182,183. Global deletion of GP-96 is embryonically lethal and not
compatible with life because it is responsible for chaperoning of multiple proteins
induction and muscle development183.
To study the effect of GP-96 on TLR expression and the immune function,
myeloid-specific GP96 deficient mice were generated and extensively studied.
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LysM-Cre/ GP-96fl/fl is highly macrophage selective, without affecting other cell
populations180.

Macrophage-specific

GP-96 deficient

mice

have

normal

hematopoiesis and normal immune cell numbers (e.g. macrophages, dendritic
cells, and leukocytes). In-vivo studies revealed that macrophage-specific GP-96
deficient mice had a significant decrease in the production of pro-inflammatory
cytokines and were relatively resistant to endotoxic shock induced by LPS injection
(TLR4 ligand). GP-96 is capable of activating the TLR signaling pathways
determined by the ability to induce pro-inflammatory cytokine/chemokines. In vitro
studies demonstrated that macrophages isolated from macrophage-specific GP96 deficient mice significantly reduced production of pro-inflammatory cytokines
such as TNF-α upon stimulation with TLRs agonist, indicating the role of GP-96 in
TLR expression180,182.
Toll like receptors (TLRs) are the best characterized pattern recognition
receptors (PRRs).They are prominently involved in the first line defense against
infection by recognizing conserved motifs expressed by pathogens called
pathogen-associated molecular patterns (PAMPs) and thereby initiate the innate
immune response. TLRs are highly expressed by a number of immune cells such
as macrophages and dendritic cells (DCs) as well as non-immune cells such as
epithelial cells and fibroblasts184,185. To date, thirteen functional TLRs have been
identified in mouse that are either expressed on the cell surface and recognize
microbial membrane components (e.g. TLR1, TLR2, TLR4, TLR5, TLR6, TLR11,
and TLR12) or are associated with intracellular vesicles and recognizes nucleic
acids (e.g. TLR3, TLR7, TLR8, TLR9 and TLR13)186. The role of TLRs in
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atherosclerosis development is still controversial. Recent evidence suggests that
TLRs have both protective and detrimental roles in atherosclerosis. Previous study
suggests a detrimental role for TLR signaling in atherosclerosis, demonstrating
that the whole-body deficiency of MyD88 reduced both atherosclerotic lesion
development and macrophage accumulation in apoE−/− mice. This study was
confirmed and followed by another study demonstrating that whole body
TLR2/TLR4 deficiency in murine models of atherosclerosis results in a significant
reduction in atherosclerotic lesion formation via inhibition of lipid deposition,
inflammatory cell recruitment and activation187,188. Other studies showed the
athero-protective functions of TLRs in atherosclerosis189,190.
Blocking TLRs signaling in the macrophage is considered to be a promising
strategy to halt the inflammation and attenuate atherosclerosis. While GP-96 has
been shown to modulate both the innate and adaptive immune systems by
controlling most TLRs, the role of GP-96 in atherosclerosis has not been
investigated. To address the role of GP-96 in immune responses during
atherogenesis, we transplanted macrophage-specific GP-96 deficient or WT bone
marrow cells into LDLR−/− mice and fed them a western diet for 9 weeks. Recipient
mice reconstituted with macrophage-specific GP-96 deficient bone marrow cells
had no significant difference in inflammation compared with control mice
transplanted with WT bone marrow cells. In addition, macrophage-specific GP-96
deficient mice displayed a comparable serum lipid, resulting in unchanged
atherosclerosis in LDLR−/− mice.
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4.2 Material and Methods
Mice
Six to eight week-old female LDLR−/− mice (C57BL/6J background) were
purchased from the Jackson Laboratory (Bar Harbor, MA, USA). Mice were
maintained in pathogen-free conditions at the University of South Carolina Animal
Research Facility according to National Institutes of Health (NIH) guidelines. All
animal experiments were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of South Carolina.
Bone Marrow Transplantation (BMT) and atherosclerosis induction
BMT was performed as previously described in chapter 2. Briefly, six to
eight week-old female LDLR−/− mice were maintained on antibiotic water
containing 100 mg/L neomycin and 10 mg/L polymyxin B, one week before and 2
weeks after BMT. Six hours before BMT, recipient mice were lethally irradiated
(900 rad) using a cesium gamma source. Bone marrow cells were harvested by
flushing both femurs and tibias from WT or macrophage-specific GP-96 deficient
mice (kindly provided by Dr. Zihai Li at the Medical University of South Carolina)
with sterile RPMI-1640 medium (Invitrogen Life Technologies, Grand Island, NY,
USA) containing 2% fetal bovine serum (Invitrogen, Grand Island, NY, USA) and
heparin (5 units/mL, Sigma, St. Louis, MO, USA). The cell suspension was
centrifuged for 5 minutes at 300 x g and re-suspended in ice cold phosphate buffer
saline (PBS). Five million bone marrow cells from donor mice were injected into
the retro-orbital venous plexus of the recipient irradiated LDLR−/− mice. After 4
weeks recovery, mice were fed a western diet containing 21% (w/v) anhydrous
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milkfat, 34% (w/v) sucrose, and a total of 0.2% (w/v) cholesterol (Harlan
laboratories; Indianapolis, IN, USA) for a duration of 9 weeks, after which mice
were sacrificed (Figure 4.1). During a western diet period, mouse food intake and
body weight were measured weekly throughout the study.
Peritoneal macrophage isolation and culture
Mice were injected i.p. with 3 mL of 3% (w/v) thioglycolate solution (BD
Biosciences Clontech; Palo Alto CA, USA). Three days later, mice were
anesthetized with isoflurane, and macrophages were obtained by washing
peritoneal cavity with 10 mL of cold PBS twice. The cells were then re-suspended
in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Grand
Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), a combination
of penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA), and 50 μM of βmercaptoethanol. After incubation for 2 hours at 37°C, non-adherent cells were
washed away with PBS, and adherent cells were cultured overnight in serum free
DMEM. Then macrophages were treated with DMEM containing LPS (50 ng/mL,
Sigma-Aldrich, St. Louis, MO, USA) for 6 hours. Next, cells were washed with
Dulbecco’s phosphate-buffered saline (DPBS) twice before being lysed for total
RNA or protein extraction.
Assessment of successful bone marrow reconstitution
The success of bone marrow reconstitution of LDLR−/− mice was
determined at the experiment endpoint. Isolated peritoneal macrophages were
lysed in Trizol reagent for PCR analysis or in RIPA buffer for western blot analysis.
GP-96 mRNA and protein levels were detected.

93

RNA extraction, cDNA synthesis, and quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Life Technologies, Grand
Island, NY, USA) according to the standard protocol. One microgram of RNA of
each sample was reverse transcribed into cDNA using iScript™ cDNA Synthesis
Kit (Bio-Rad Life Science, Hercules, CA). qRT- PCR was performed using iQ™
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA) according to the
manufacturers’ instructions. The relative amount of target mRNA was determined
using the comparative threshold (Ct) method by normalizing target mRNA Ct
values to those of 18S RNA. PCR thermal cycling conditions were 3 min at 95°C,
and 40 cycles of 15 s at 95°C and 58 s at 60°C. Samples were run in triplicate.
The primers used for qRT-PCR are shown in table 4.1.
Western blot analysis
After 9 weeks of western diet, peritoneal macrophages were isolated,
cultured, and incubated in the absence or presence of LPS (50 ng/mL) for 24
hours. To obtain the total cell lysates, the attached cells were incubated and lysed
for 30 min on ice in RIPA buffer (PierceTM, Rockford, IL, USA) supplemented with
protease inhibitor cocktail and phosphatase inhibitors (Sigma-Aldrich, St. Louis,
MO, USA). Equal amounts of total cell proteins (30 µg) were separated in 4-20 %
SDS-PAGE pre-cast gels (Bio-Rad, Hercules, CA, USA) for electrophoresis and
transferred onto Nitrocellulose membranes (Millipore Corp., Bedford, MA, USA).
After blocking with 5% non-fat dry milk, primary antibodies and HRP-conjugated
secondary antibodies were used to detect target proteins. Signal was detected
using Pierce ECL Western Blotting Substrate (PierceTM, Rockford, IL, USA). For
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stripping, membranes were submerged for 30 minutes at 55 – 60°C in a buffer
containing 100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris-HCl, pH 6.7,
and washed three times with PBST.
Serum lipid and lipoprotein distribution analysis
After an overnight fast, ~ 500 µL blood was collected from each mouse by
retro-orbital venous plexus puncture and centrifuged at 4,000 x g for 20 min. Serum
total cholesterol and triglyceride levels were determined by enzymatic colorimetric
assays with Cholesterol Reagent and Triglycerides GPO reagent kits (Raichem,
San Diego, CA, USA), and analyzed by SoftMax Pro5 software (Molecular
Devices, Sunnyvale CA, USA). Serum lipoproteins were determined using a fastperformance liquid chromatography (FPLC) system (AKTA purifier, GE Healthcare
Biosciences, Pittsburgh, PA, USA) equipped with a Superose 6 10/300 GL column
(GE Healthcare). Pooled mouse plasma (100 µL) was loaded into the column, and
eluted at a constant flow rate of 0.5 mL/min with 1 mM sodium EDTA and 0.15 M
NaCI. Fractions of 0.5 mL were collected and cholesterol concentration from each
fraction was measured.
Blood glucose measurement
OneTouch Ultra Blood Glucose Monitoring System (LifeScan, Inc., Milpitas,
CA, USA) was used to measure the blood glucose concentration following the
manufacturer’s instructions.
Flow cytometry analysis
After 9 weeks of western diet feeding, the mice (not thioglycollate
stimulated) were sacrificed. Spleens were obtained and smashed in 10 mL RPMI-
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1640 medium supplemented with 10% FBS using Stomacher® 80 Biomaster
(Seward Laboratory Systems Inc., Port St. Lucie, FL, USA). Red blood cells in
spleen samples were lysed using red blood cell lysing buffer (Sigma-Aldrich, St.
Louis, MO, USA). To obtain single cell suspensions, tissue were passed through
a 70 µM cell strainer (Life Sciences, Tewksbury, MA, USA). Cells were fixed,
permeabilized, and stained for 30 min on ice in dark using the following antibodies:
PE-anti-CD3,

FITC-anti-CD4,

FITC-anti-CD8a,

FITC-anti-CD19,

FITC-anti-

CD11c, PE-anti-CD11b, FITC-anti-Ly6C, FITC-anti-Ly6G, and FITC- anti -F4/80
mAb (eBioscienceTM, Invitrogen) in staining buffer. Stained cells were acquired on
a Cytomics FC 500 flow cytometer and further analyzed with CXP software version
2.2 (Beckman Coulter, Brea, CA, USA). Data were collected for 10,000 live events
per sample.
Bioplex analysis of serum cytokine/chemokines
Serum levels of 23 cytokine/chemokines from mice were measured using a
Bio-Plex ProTM Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA, USA) on
a Bio-Plex system following the manufacturer’s instructions.
Atherosclerosis analysis
To induce atherosclerosis, mice were fed a western diet for 9 weeks. At the
experimental endpoint, mice were sacrificed and their vasculature perfused with
10 mL of cold PBS via cardiac puncture to remove blood contamination from
vascular tissue. Hearts and aortas were dissected, and the aortic root was isolated
and embedded in OCT compound in a plastic mold, frozen at - 20 ⁰C, and cut into
10 µm sections. For the aortic enface assay, aortas were fixed in 10% neutral
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buffered formalin, cleaned, opened longitudinally, pinned onto black wax plates,
and stained with Sudan‐IV (Sigma‐Aldrich, St. Louis, MO, USA). The lesion areas
were quantified and analyzed by ImageJ software. Atherosclerotic lesion areas in
the aortic root were visualized with H&E staining, and lipid-deposition with ORO
staining and quantified by Image-Pro Plus 6.0 as previously described in chapter
3. For macrophage analysis, rat anti-mouse MOMA2 (Abcam, Cambridge, MA,
USA) was used for immunostaining on serial sections of the aortic root, and
biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) was
used as the secondary antibody. Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA) was used to amplify the immunoreactivity, and signal was
enhanced by Peroxidase Enhancer (GeneTex, Irvine, CA, USA), and finally
reacted with the substrate from AEC Chromogen/FRP substrate kit (GeneTex,
Irvine, CA, USA). Masson’s trichrome staining was used as previously described
in chapter 3 to detect collagen content in the aortic root sections. All images were
recorded with a Nikon E600 Wide field Epifluorescence microscope and
Micropublisher digital camera with Q-imaging software. Data were quantified by
computerized image Pro-Plus.
Statistical analyses
Data were presented as mean ± SEM. Statistical significance was
calculated by Student’s t test for two-group comparison or one-way analysis of
variance (ANOVA) for multi-group comparison using the Graph-Pad Prism
statistical program (Graph-Pad Software, Inc., San Diego, CA). p<0.05 was
considered statistically significant.
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4.3 Results
Efficiency of macrophage-specific GP-96 knockout
After bone marrow transplantation and 9 weeks of western diet, PCR and
western blot analysis were used to confirm the efficiency of macrophage-specific
GP-96 knockout. Macrophage-specific GP-96 deficient mice exhibit a significant
loss (but not complete absence) of GP-96 in peritoneal and splenic macrophages,
while the GP-96 expression was unaffected in splenic B-cells and T-cells (Figures
4.2A, 4.2B and 4.2C).
As GP-96 is the master chaperone for multiple TLRs, we next detected the
expression of TLR4 in peritoneal macrophages using western blot analysis.
Macrophage-specific GP-96 deficient macrophages displayed a significant
decrease in TLR4 expression (Figure 4.2D).
Macrophage-specific GP-96 deficiency does not affect mouse food intake
and body weight
We transplanted five million bone marrow cells from either WT (control) or
macrophage-specific GP-96 deficient mice to lethally irradiated LDLR−/− mice. Four
weeks following the bone marrow transplantation, the recipients LDLR −/− mice
were fed a western diet for 9 weeks to induce atherosclerosis. During the western
diet feeding period, we measured the food intake and body weight weekly.
Throughout the experiment, macrophage-specific GP-96 deficient mice and control
mice showed no difference in food intake (Figure 4.3A) and body weight (Figure
4.3B).
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Macrophage GP96 is not required for the inflammatory response during
atherosclerosis progression
The effect of macrophage-specific GP96 deficiency on inflammation has
been examined. Initially, the spleen weight was measured at the experimental
endpoint. No significant differences were observed between the two groups
(Figure 4.4A). Next, flow cytometric analysis of the splenocytes was performed to
determine the leukocyte population in the spleen. Several different leukocyte
populations were investigated and the results showed that there were no
significant differences in the percentage of leukocyte populations in the spleen
between macrophage-specific GP96 deficient mice and control mice (Figure 4.4B).
To obtain further insight into the role of macrophage-specific GP96
deficiency in systemic inflammation during atherosclerosis, we measured serum
levels of cytokine/chemokines using Bio-plex assays. We found that there was no
difference in these cytokine/chemokines between the two groups (Figure 4.4C).
This indicates that macrophage-specific GP96 deficiency did not significantly affect
inflammation in LDLR−/− mice.
Macrophage-specific GP96 deficiency does not affect serum lipid levels
After 9 weeks of western diet feeding, serum cholesterol and triglyceride
levels were measured and there were no significant differences between the
macrophage-specific GP-96 deficient group and the control group (Figures 4.5A
and 4.5B). Analysis of the plasma lipoprotein profile by FPLC showed no significant
difference in VLDL, LDL and HDL cholesterol fractions in macrophage-specific GP96 deficient mice compared to the control mice (Figure 4.5C). In addition, blood
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glucose levels were comparable between the two groups (Figure 4.5D). These
findings indicated that macrophage-specific GP-96 deficiency did not affect serum
lipid levels.
Macrophage-specific GP-96 deficiency does not influence progression of
atherosclerosis
Bone marrow recipient mice were sacrificed and the extent of early stages
of atherosclerosis in the aorta and aortic root were analyzed. A comparable lesion
size in the aorta and aortic root was observed between macrophage-specific GP96 deficient mice and control mice (Figure 4.6A and 4.6B). Moreover, all
parameters of plaque complexity including lipid accumulation (Figure 4.6C),
macrophage infiltration (Figure 4.6D) as well as collagen content (Figure 4.6E) in
the atherosclerotic lesions were similar between the two groups of mice. This
indicates that macrophage GP-96 is dispensable for both inflammation and
atherosclerosis development in LDLR−/− mice.
4.4 Discussion
GP-96 has been implicated in antigen presentation and activation of the
innate and adaptive immunity191. GP-96 participates in the folding and assembly
of many secretory and membrane proteins, and is essential for the cell-surface
expression of TLRs including TLR2 and TLR4180,192. Given the fact that GP-96
deficiency is associated with loss of multiple TLRs, macrophage-specific GP-96
deficient mice are relatively resistant to shock induced by systemic administration
of LPS (TLR4 ligand), and macrophages isolated from these mice showed a
significant decrease in cytokine production upon stimulation with multiple TLR
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agonists, we aimed to investigate if the reduced TLR dependent responsiveness
of GP-96 deficient macrophages would result in reduced inflammation and
subsequently attenuated atherosclerosis in hyperlipidemic mice. The major finding
in this study is that macrophage-specific GP-96 deficiency did not result in
alteration in atherosclerosis in high fat diet-fed LDLR−/− mice, suggesting that GP96 does not play a significant role in macrophage inflammatory response in
atherogenesis.
GP-96 contributes to the correct functioning of TLR mediated responses.
Myeloid GP-96 deficiency leads to loss of multiple TLRs including TLR1-9 except
TLR3180. Increasing evidence suggests that TLRs are key orchestrators in
atherosclerosis development. Activation of all TLRs except TLR3 triggers an
intracellular signaling pathway mediated by myeloid differentiation primaryresponse protein 88 (MyD88) or TIR domain-containing adaptor inducing IFN-β
(TRIF), leading to the production of pro- and anti-inflammatory cytokines193.
Previous evidence suggests that MyD88 plays a significant role in atherosclerosis.
Deletion of the MyD88 gene in apoE−/− mice results in a significant reduction in
aortic atherosclerosis and reduced macrophage accumulation194. However, bone
marrow transplantation of MyD88 deficient DCs to LDLR−/− mice had
atheroprotective effect195. The role of TLRs in atherosclerosis is still controversial;
deficiency of TLRs in atherosclerosis mouse models showed conflicting effects on
atherogenesis, e.g. TLR2/LDLR deficient mice developed less atherosclerosis
compared to LDLR−/− mice. This result was confirmed in apoE

−/−

mice. However,

no difference was observed in bone marrow transplantation studies, this finding
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suggests that selective TLR2 cellular-type expression contributes differentially to
lesion development196,197 . TLR1 and TLR6 did not affect atherosclerosis
development in high fat diet-fed LDLR−/− mice198. Genetic deletion of TLR4
dramatically

reduced

macrophage

infiltration

and

atherosclerotic

lesion

development in apoE−/− mice187; whereas transplantation of TLR2/TLR4 deficient
bone marrow cells to LDLR−/− mice fed a high fat diet did not result in changes in
atherosclerosis198. Furthermore, TLR3 has been shown to be atheroprotective as
the TLR3−/−/apoE−/− mice had more atherosclerosis than ApoE−/− mice189. Taken
together, these studies showed conflicting outcomes of TLR manipulation
depending on experimental conditions and models. Our study added another
example of the complex role of TLRs in atherogenesis.
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Table 4. 1 Primers that were used for qRT-PCR in this study
Primers

Forward (5’  3’)

Reverse (5’  3’)

18s

CGCGGTTCTATTTTGTTGGT

AGTCGGCATCGTTTATGGTC

mGP-96

CATTTGAAATCAGTTCTCTCAG AACGCATCACAGATAAGAGA
GA

AC

mTNF-α

CGT CAGCCG ATTTGCTAT CT

CGGACTCCGCAAAGTCTAAG

mIL6

AGTTGCCTTCTTGGGACTGA

TCCACGATTTCCCAGAGAAC
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Figure 4. 1 In vivo experimental design, mouse model and bone marrow
transplantation used for assessment of atherosclerosis
Six to eight week-old female LDLR−/− mice were provided with antibiotics water
containing neomycin (100 mg/L) and polymyxin B sulphate (60.000 U/L) one week
before and two weeks after BMT. Mice received total body irradiation. Bone
marrow cells were isolated from macrophage-specific GP-96 deficient mice or WT
mice and 5 x 106 cells were injected into LDLR−/− mice in the retro-orbital plexus.
Four weeks after the BMT, mice were fed a western diet for 9 weeks.
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Figure 4. 2 Characterization of macrophage-specific GP-96 deficient mice
Expression of the GP-96 isolated from peritoneal macrophages of macrophagespecific GP-96 deficient mice and control (WT mice) (n = 3 per group) was
examined by PCR (A) and western blot (B). Expression of GP-96 protein in
macrophage, B cells and T cells isolated from spleen of macrophage-specific GP96 deficient mice and WT mice (C). Expression of TLR4 in peritoneal macrophages
was assessed by western blot (n=3 per group).
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Figure 4. 3 Effect of macrophage-specific GP-96 deficiency on mouse body
weight, and food intake
LDLR−/− mice were transplanted with bone marrow cells from macrophage-specific
GP-96 deficient mice or control mice, allowed to recover for 4 weeks and
subsequently fed a western diet for 9 weeks. Food intake (A) and body weight (B)
were monitored weekly during the whole experiment.
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Figure 4. 4 Effect of macrophage-specific GP-96 deficiency on inflammation
(A) Spleen weight, (B) Flow cytometric analysis of splenocytes of LDLR−/− mice
transplanted with bone marrow cells from macrophage-specific GP-96 deficient or
WT mice and fed a western diet for 9 weeks. (C) Serum cytokine/chemokines were
measured by Bio-Plex assays.
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Figure 4. 5 Effect of macrophage-specific GP-96 deficiency on serum lipids
After 9 weeks of western diet feeding, blood samples were drawn from retro-orbital
puncture and the concentrations of cholesterol (A) and triglycerides (B) in the
serum were determined. The distribution of cholesterol over the different
lipoproteins was determined by FPLC. Cholesterol content in VLDL, LDL, and HDL
fractions were measured (C). Fast blood glucose levels were determined (D).
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Figure 4. 6 Effect of macrophage-specific GP-96 deficiency on
atherosclerotic lesion development
After 9 weeks of western diet, mice were sacrificed and their aortas and hearts
were dissected. Aortas were cleaned, fixed in 10 % PFA, and stained with Sudan
IV en face (A). Cross-sections throughout the aortic root area starting from the
appearance of open aortic valve leaflets were used for atherosclerosis
measurements. (B) Representative images and quantification of lesion area
stained with H&E. (C) Representative images and quantification of lipid content in
the aortic root as determined by ORO staining. (D) Representative images and
quantification of aortic root macrophage infiltration as detected by immunostaining
using MOMA-2 antibody. (E) Representative images and quantification of aortic
root collagen content stained with trichrome.
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Chapter V
The therapeutic value of an anti-inflammatory Chinese herb compound,
SsnB, for atherosclerosis
5.1 Background
Amounting clinical studies have shown that persistent low-grade
inflammation is associated with the pathogenesis of chronic diseases such as
atherosclerosis. Although high dose endotoxemia causes a significant increase in
the inflammatory cytokines and acute tissue damage, low levels of circulating LPS
have been implicated in initiating low-grade inflammation by mild and persistent
increase in the expression of pro-inflammatory cytokines199. Low-grade
endotoxemia may change the host immune environment into a mild non-resolving
pro-inflammatory state, which eventually leads to slow and progressive tissue
damage, leading to the pathogenesis and progression of chronic inflammatory
diseases200. Recently, it has been shown that super-low dose LPS administration
significantly promoted inflammation and exacerbated steatohepatitis in high fat
diet-fed apoE−/− mice201.
Sparstolonin B (SsnB) is a newly described, bioactive natural compound
isolated and characterized from the Chinese herb Sparganium stoloniferum tubers
which are used in Traditional Chinese Medicine (TCM) as a safe, non-toxic
pharmaceutical agent for the treatment of several inflammatory diseases and as
an anti-tumor agent. Our laboratory first isolated the compound and determined its
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structure using NMR spectroscopy and X-ray crystallography. We showed that
SsnB is a polyphenol with structural features of xanthone and isocoumarin , which
has anti-oxidation and anti-inflammatory property202. We have previously shown:
1) SsnB is a selective inhibitor of TLR2/TLR4 mediated inflammatory signaling via
disruption of TIRAP/MyD88 interaction202; 2) SsnB attenuates inflammation and
reduces production of inflammatory cytokines in macrophages and endothelial
cells by selectively blocking TLR2/TLR4 signaling202,203; 3) SsnB significantly
inhibited VSMCs proliferation, migration, inflammatory responses, and lipid
accumulation in vitro204; 4) SsnB strongly attenuated cardiomyocyte inflammation
in an ischemia/reperfusion injury model in vitro205; 5) SsnB inhibits pro-angiogenic
functions and blocks cell cycle progression in human umbilical vein endothelial
cells (HUVECs)206; and 6) SsnB is able to protect mice against endotoxin shock
via inhibiting production of multiple cytokines and to attenuate hypoxia-induced
apoptosis, necrosis, and inflammation in cultured rat left ventricular tissue slices 207.
All of these studies suggested that SsnB may act as a potential therapeutic agent
for inflammatory diseases, such as atherosclerosis. Given the facts that
macrophages and VSMCs play a significant role in atherosclerosis, and the antiinflammatory properties of SsnB on endothelial cells, VSMCs, and macrophages,
we expected that SsnB could be a promising new agent for the prevention and
treatment of inflammatory cardiovascular atherosclerotic diseases. In this study we
tested the effect of SsnB on vascular inflammation and atherosclerosis
development in an atherogenic mouse model after super-low dose LPS
administration. We hypothesized that super-low dose LPS injection would promote
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low grade chronic inflammation, and that SsnB may reduce the LPS induced
inflammation and thereby attenuate atherosclerosis development.
5.2 Material and Methods
Mouse models
Six to eight week-old female LDLR−/− mice on C57BL/6J background were
purchased from the Jackson Laboratories (Bar Harbor, MA, USA) and maintained
in pathogen-free conditions at the University of South Carolina Animal Research
Facility according to National Institutes of Health (NIH) guidelines. All animal
experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of South Carolina. Mice were placed on a western diet
containing 21% (w/v) anhydrous milk-fat, 34% (w/v) sucrose, and a total of 0.2%
(w/v) cholesterol (Harlan laboratories, Indianapolis, IN, USA) for 10 weeks. After
two weeks of western diet, mice were randomly divided into 3 groups as follows:
(1) LPS group, injected intraperitoneally (i.p.) with super-low dose LPS (4 ng/kg
body weight, ~100 pg/mouse) dissolved in endotoxin free PBS; (2) SsnB group,
injected i.p. with SsnB (4 mg/kg body weight) plus LPS (4 ng/kg body weight), and
(3) PBS group, injected i.p. with the same volume of PBS (No LPS). Initially, mice
were injected every other day for the first 4 weeks, then twice a week for another
4 weeks. Body weight and food intake were monitored weekly. At the experimental
endpoints, all mice were sacrificed; blood and serum were collected for analysis,
aortas and aortic roots were harvested for atherosclerosis analysis. Liver samples
were lysed in Triazol for qPCR.
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VetScan hematology analysis
Blood was collected from retro-orbital puncture into heparinized tubes.
Blood samples were run on the VetScan HMT hematology analyzer (Abaxis, Union
City, CA, USA). Different blood parameters were detected: total red blood cells
(RBC), hemoglobin, mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), hematocrit (Hct), platelet number, mean
platelet volume (MPV), platelet distribution width (PDW), total white blood cells
(WBC), lymphocytes, mean cell volume (MCV), and red cell distribution width
(RDW).
Serum lipid analysis
Total serum cholesterol and triglyceride levels were measured using
enzymatic colorimetric assays with Cholesterol Reagent and Triglycerides GPO
reagent kits (Raichem; San Diego, CA, USA) and analyzed by SoftMax Pro5
software (Molecular Devices, Sunnyvale CA, USA). Briefly, retro-orbital venous
blood was collected. Serum was obtained via centrifugation at 4000 x g for 20
minutes. Then, serum was diluted 1:100 in sterile water, 100 µL was loaded on the
microplate well and 100 µL of freshly prepared cholesterol and triglyceride reagent
were added to wells. The plates were incubated 10 minutes at 37⁰C and the
absorbance was measured at 540 nm.
Blood glucose measurement
Blood glucose concentration was measured using OneTouch Ultra Blood
Glucose Monitoring System (LifeScan, Inc., Milpitas, CA, USA) following the
manufacturer’s instructions.
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Bio-plex analysis of serum cytokine/chemokines
Mouse serum levels of 23 cytokine/chemokines were measured using a BioPlex ProTM Mouse Cytokine 23-plex Assay (Bio-Rad, Hercules, CA, USA) on a BioPlex system following the manufacturer’s instructions.
Alanine Aminotransferase (ALT) measurement
Liver function was assessed by measuring plasma alanine amino
transferase (ALT) levels. At the experimental endpoint, blood was collected and
serum isolated by centrifugation at 4000 x g for 20 minutes. ALT levels were
measured using a Liquid ALT (SGPT) Reagent Set (Pointe Scientific, Inc. Canton,
MI, USA) according to the manufacturer’s instructions.
RNA extraction, cDNA synthesis, and quantitative real-time PCR
Total mRNAs were extracted from liver tissue using Trizol reagent
(Invitrogen) following the manufacturer’s instructions. One microgram of isolated
mRNA was reverse transcribed into cDNA in 20 μL reactions using iScriptTM cDNA
synthesis kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed on a BioRad CFX96 system (Bio-Rad, Hercules, CA, USA) using iQ™ SYBR® Green
Supermix (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s
instructions. The relative amount of target mRNA was calculated using the 2 (-ΔΔCt)
method by normalizing target mRNA Ct values to those of housekeeping gene,
18S mRNA expression. PCR thermal cycling conditions were 3 minutes at 95°C,
and 40 cycles of 15 s at 95°C and 58 s at 60°C. Samples were run in triplicate.
Primers used are listed in table 5.1
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Quantification of atherosclerosis
At the experimental end point, mice were sacrificed. The aortas and aortic
root were collected and processed as previously described in chapter 3 for
atherosclerosis analysis. Aortas were stained with Sudan IV for aortic enface
assay. Aortic root sections were stained with H&E, ORO, immunostaining using
MOMA-2 antibody, and Masson’s trichrome to measure the atherosclerotic plaque
area, lipid deposition, macrophage infiltration, and collagen percentage
respectively. All images were recorded with a Nikon DS-Ri2 microscope and
Micropublisher digital camera with Q-imaging software. Plaque size, lipid content,
collagen percentage and macrophage cell content were quantified by
computerized image Pro-Plus.
Statistical analyses
Data were presented as mean ± standard error of the mean (SEM).
Statistical analysis was performed with GraphPad Prism 6.0 software (GraphPad
Software Inc, San Diego, CA, USA). Statistical significance was determined by
one-way analysis of variance (ANOVA) for multi-group comparison and Student’s
t test for two-group comparison. Data were considered statistically significant at *P
< 0.05, **P<0.01, and ***P<0.001.
5.3 Results
SsnB treatment and super-low dose LPS administration did not affect mouse
food intake and body weight
To induce atherosclerosis, LDLR−/− mice were fed a western diet for 10
weeks to induce hyperlipidemia. After two weeks of western diet, mice were
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divided into three groups. In the first group, mice were injected i.p. with super-low
dose LPS (4 ng/kg body weight). While in the second group, mice were injected
i.p. with SsnB (4 mg/kg body weight) along with LPS (4 ng/kg body weight), in the
third group, mice were injected i.p. with 1 mL PBS. Food intake and body weight
of the mice were monitored weekly. We did not observe significant differences in
body weight and food intake between the groups over the course of the experiment
(Figure 5.1A and 5.1B).
SsnB treatment and super-low dose LPS administration did not affect blood
cell profile
To examine the effect of SsnB treatment after super-low dose LPS
administration on blood cell profile, we performed a detailed hematological
analysis. Vetscan HMT analysis indicated that there were no significant differences
in all blood parameters including total white blood cells and white blood cell
differential count, red blood cell number, hemoglobin concentration and
hematocrit, Total blood platelet numbers and platelet hematocrit between the
groups (Figures 5.2A, 5.2B, and 5.2C).
SsnB treatment and super-low dose LPS administration did not affect serum
lipid levels and blood glucose levels
After 10 weeks of western diet and 8 weeks of super-low dose LPS and
SsnB treatment, mice were fasted overnight, sacrificed, blood were collected and
serum isolated as previously described. Serum total cholesterol and triglyceride
levels were measured as well as fasting blood glucose levels. We did not observe
any significant difference in the serum total cholesterol (Figure 5.3A), triglyceride
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(Figure 5.3B), and fast blood glucose levels (Figure 5.3C) between PBS, LPS and
SsnB groups. Indicating that superlow dose LPS administration and SsnB
treatment did not affects lipid profile.
SsnB treatment reduced serum chemokines induced by super-low dose LPS
administration
Chronic injection of subclinical super-low dose LPS has been shown to
sustain a low grade inflammation in vitro and in vivo201,208. Furthermore, SsnB
treatment dramatically reduced macrophage and endothelial cell inflammation in
vitro202,203. We measured the spleen weight for these mice and found no difference
between the groups (Figure 5.4A). We next detected the effects of super-low dose
LPS and SsnB treatment on the inflammation in LDLR−/− mice fed a western diet
by measuring several cytokine/chemokines levels in the serum using Bio-Plex
assay. In agreement with a previous study201 several inflammatory biomarkers
including keratinocyte-derived chemokine (KC), Macrophage inflammatory protein
(MIP1-α and MIP1-β), and RANTES were increased by super-low dose LPS
injection. Furthermore, SsnB treatment was able to significantly reduce the
inflammatory chemokines p-value 0.0121, 0.0240, 0.0452 respectively (Figure
5.4B).

These

chemokines

are

potent

macrophage

and

lymphocyte

chemoattractants and play a critical role in chronic inflammation. Macrophage
inflammatory proteins (MIPs) are markedly up-regulated in macrophages upon
exposure to bacterial LPS and increase their ability to recruit more inflammatory
cells209. It has been shown that KC plays a central role in macrophage infiltration
and accumulation in atherosclerotic lesions in mice210. In addition to that, some
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other inflammatory cytokines such as IL3 and IL12(P40) were slighly increased
after super-low dose LPS injection and SsnB slightly reduced these cytokines but
without statistical significance.
SsnB treatment has no impact on atherogenesis in LDLR−/− mice
administered with super-low dose LPS and fed an atherogenic diet
For atherosclerotic lesion analysis, the aorta and aortic root were isolated
for atherosclerosis staining. In brief, the aortic roots were embedded in OCT for
cryo-sectioning. Aortas were fixed in 10% neutral buffered formalin and stained
with Sudan IV for the aortic enface analysis. The results showed that most of the
lesions were localized specifically in the aortic sinus and aortic arch. The superlow dose LPS injection as well as SsnB treatment did not significantly affect
atherosclerotic lesion area of the aorta as and aortic root after 10 weeks of western
diet (Figure 5.5A and 5.5B). Furthermore, the super-low dose LPS injection and
SsnB treatment did not significantlly affect lipid deposion, lesional MOMA-2
positive macrophage infiltration, and collagen deposition in the aortic root lesions
(Figure 5.5C, 5.5D, and 5.5E).
Effects of SsnB treatment on liver function after super-low dose LPS
administration
Subclinical super-low dose LPS administration has been shown to initiate
low grade-chronic inflammation and exacerbates liver inflammation as well as lipid
accumulation201,208. We have shown previously that SsnB administrarion in
experimental animal models attenuates early liver inflammation and injury in toxininduced steatohepatitis211. We therfore examined the effects of super-low dose
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LPS injection and SsnB treatment on liver function in our experimental mouse
model. At the experimental endpoint, we measured liver weight. Niether super-low
dose LPS nor SsnB treatment changed the liver weight at the experimental
endpoint (Figure 5.6A). Further, we collected serum from mice and examined the
liver function by detecting serum ALT levels. As previously reported201, our results
showed that super-low dose LPS administration slighly increased plasma ALT
levels compared to the PBS group but without statistical significance. However,
SsnB treatment did not affect ALT levels (Figure 5.6B). qRT-PCR was used to
examine the expression levels of pro-inflammatory cytokines in the liver tissue.
LDLR−/− mice injected with super-low dose LPS had a higher expression of
inflammatory markers such as TNF-α and IL-6 compared to PBS group. Whereas,
SsnB treatment slightly reduced the LPS induced IL6 expression and made no
difference in TNF-α expression levels (Figure 5.6C and 5.6D).
5.4 Discussion
Atherosclerosis is a complex process involving many steps. Several lines
of evidence ranging from animal experimental models to epidemiological studies
support the notion that inflammation is one of the driving forces of
atherogenesis22,62. However, the current treatments of atherosclerotic diseases
are focused exclusively on reducing plasma lipid levels rather than reducing the
harmful effects of acute and chronic inflammation. Recently, there has been
intense interest in exploring specific anti-inflammation therapies to reduce the risk
of cardiovascular diseases and offer an opportunity to directly test the inflammation
hypothesis of atherosclerosis. Therefore, modulating systemic and local
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inflammatory responses and targeting different inflammatory pathways might be
effective in the treatment/prevention of atherosclerosis and may thereby reduce
the risk of CVDs22,31,109.
High dose LPS injection has been shown to significantly aggravate
atherosclerosis via the activation of the nuclear factor kappa-B (NF-κB) pathway
to secrete pro-inflammatory cytokines, including IL-6, MCP-1, and TNF-α212; but
high dose LPS is not commonly observed in humans and thus not particularly
clinically relevant. Subclinical super-low dose LPS is associated with persistent
non-resolving chronic low-grade inflammation during the pathogenesis and
progression of chronic diseases such as atherosclerosis and diabetes; and chronic
exposure to low or very low dose of LPS is common and clinically relevant. Unlike
high dose LPS, the super-low dose LPS does not activate NFκB pathway or induce
the anti-inflammatory mediators213,214. Therefore, strategies targeting this low
grade inflammation may demonstrate significant promise in not only the treatment,
but also the reversal and prevention of chronic inflammatory diseases.
A Chinese herb-derived compound, sparstolonin B (SsnB), selectively
blocks TLR2/TLR4 mediated inflammatory signaling pathways such as MAPK and
NF-κB pathways in macrophages202,215. SsnB has been shown to significantly
reduce the expression of pro-inflammatory cytokines in high dose LPS-challenged
mice202. However, the effect of SsnB on inflammation and atherosclerosis in
atherogenic mice after super-low dose LPS administration has not been
elucidated. In the present study, we found that super-low dose LPS and SsnB
administration for 8 weeks did not affect mouse food intake and body weight after
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10 weeks of western diet. In addition, blood cell profile and serum lipid levels did
not change with SsnB treatment after super-low dose LPS administration. On the
other hand, super-low dose LPS administration increased serum chemoattractant
chemokines (RANTES, MIP1-α, and KC) and SsnB treatment attenuated the
increase of these chemokines. Our study also showed that subclinical super-low
dose LPS and SsnB treatment did not significantly alter lesion size in the aortic
enface and aortic root lesions. Regarding plaque composition, no significant
differences were observed in lipid deposition, macrophage infiltration and collagen
content between groups.
In conclusion, we show here that subclinical super-low dose LPS injection
in LDLR−/− mice after 10 weeks of western diet did not significantly increased
systemic inflammation and atherosclerotic lesion size at early stages as we
expected. Furthermore, SsnB administration did not significantly affect plaque size
or composition after super-low dose LPS injection. The effect of SsnB on
atherosclerosis

through

suppressing

investigations.
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Table 5. 1 Primers that were used for qRT-PCR in this study
Primers

Forward (5’  3’)

Reverse (5’  3’)

m18S

CGCGGTTCTATTTTGTTGGT

AGTCGGCATCGTTTATGGTC

mTNF-α

CGTCAGCCG ATTTGCTATCT

CGGACTCCGCAAAGTCTAAG

mIL-6

AGTTGCCTTCTTGGGACTGA

TCCACGATTTCCCAGAGAAC

123

Figure 5. 1 SsnB treatment and super-low dose LPS administration did not
affect mouse food intake and body weight
Six to eight week-old female LDLR−/− mice were fed a western diet for 10 weeks.
During the last eight weeks, the mice were injected intraperitoneally with PBS,
super-low dose LPS and SsnB. At the end of each indicated week mouse body
weights (A) and food intake (B) were measured. The average daily intake of
western diet per mouse during the week was calculated.
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Figure 5. 2 SsnB treatment and super-low dose LPS administration did not
affect blood cell profile
Vetscan HMT blood cell analysis showed: (A) white blood leukocyte profile: total
white blood cell number and white blood cell differential count (lymphocytes,
monocytes, and neutrophils numbers and percentage). (B) Red blood cell (RBC)
number, hemoglobin (HGB) concentration and hematocrit (HCT), as well as mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean
corpuscular hemoglobin concentration (MCHC), and red cell distribution width
(RDWc) which is calculated as Standard deviation ÷ mean cell volume x 100.
(C) Platelet related parameters of mice obtained by Vetscan HMT analysis.
Parameters include total blood platelet count, mean platelet volume (MVP), platelet
hematocrit (PCT), and platelet distribution width (PDWc) which is calculated using
equation RDWc(%) = (Standard deviation ÷ mean cell volume) x 100. N = 7 mice
each group.
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Figure 5. 3 SsnB treatment and super-low dose LPS administration did not
alter serum lipid and blood glucose levels
Female LDLR−/− mice were fed a western diet for 10 weeks. During the last eight
weeks, the mice were injected with LPS with or without SsnB every other day for
the first four weeks then twice a week for another four weeks. At the experimental
endpoint all mice were sacrificed and serum collected. Serum total cholesterol (A)
and triglyceride (B). Fast blood glucose levels were determined (C).
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Figure 5. 4 SsnB treatment reduced serum chemokines induced by superlow dose LPS administration
(A) Mouse spleen weight. (B) Serum levels of 23 cytokine/chemokines were
measured by Bio-Plex Pro™ Mouse Cytokine 23-plex Assay. Data are presented
as the mean ± SEM (n = 10 per group). *P < 0.05, **P < 0.01
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Figure 5. 5 SsnB treatment has no impact on atherogenesis in LDLR−/− mice
administered with super-low dose LPS and fed an atherogenic diet
LDLR−/− mice were fed a western diet for 10 weeks to induce atherosclerosis. Mice
were injected i.p. with super-low dose LPS (4 ng/kg body weight, ~100 pg/mouse)
or LPS plus SsnB (4 mg/kg body weight) for 8 weeks. (A) Representative images
and quantification of aortic enface stained with Sudan IV. (B) Representative
images and quantification of lesion area in the aortic root frozen section of the
control (PBS), LPS, and SsnB treatment mice stained with H&E. (C)
Representative images and quantification of lipid content in the aortic root frozen
section stained with ORO. (D) Representative images and quantification of
macrophage infiltration in the aortic root frozen section stained with
immunostaining using MOMA2 antibody. (E) Representative images and
quantification of collagen content in the aortic root frozen section stained with
trichrome staining. Data are presented as mean ± SEM.
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Figure 5. 6 Effects of SsnB treatment on liver function after super-low dose
LPS administration
After sacrificing, mouse liver was thoroughly perfused to remove blood and then
weighed. (A) Liver weight. (B) Serum ALT levels were determined at the end point.
(d) Liver IL6, TNF-α gene expression were examined by qRT-PCR (*P < 0.05)
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Chapter VI
Summary and conclusion
Atherosclerosis is a multi-stage and multifaceted disease. Both innate and
adaptive immunity are involved in all phases of atherogenesis, from lesion initiation
through progression and ultimately to the clinical complications of this disease 50.
All types of immune cells have been found in atherosclerotic lesions indicating that
all immune components may participate in atherogenesis. Inflammation is a basic
pathogenic element in the development and progression of atherosclerotic disease
and in its manifestation. Inflammation is caused by complex interactions involving
different cell types, different mediators, and different cellular processes. All of
these factors form the basis of the “inflammation hypothesis of atherosclerosis”45.
The relationship between inflammation and atherogenesis is complex. The link
between inflammation and atherosclerosis provides a new avenue for future
pharmacologic intervention that may slow the progression of atherosclerosis by
targeting

inflammation.

Directly

testing

the

inflammation

hypothesis

of

atherosclerosis requires drugs that have systemic anti-inflammatory effect without
affecting lipid levels. Experimental and clinical studies suggest that reducing
inflammation without affecting lipid levels may reduce the rate of CVDs 4,22,27,31.
Recently, the phase III CANTOS study demonstrated that Canakinumab (IL1-β
antibody) is the first and only drug that selectively targets inflammation and
significantly reduces cardiovascular risk in patients with a prior heart attack and
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inflammatory atherosclerosis84. IL1-β has been identified in early human
atherosclerotic plaques and mouse models of atherosclerosis suggesting a causal
role for IL-1β in atherogenesis. oxLDL, cholesterol crystals, and apoptotic cells
have been identified as endogenous triggers of the NLRP3 inflammasome and
secretion of IL-1β by plaque macrophages in atherosclerosis216. The expression of
inflammation markers in atherosclerosis has been shown to be predictive of future
cardiovascular risk. The detection of these inflammatory markers and immune
profile may lead to a better stratification of asymptomatic patients. In particular,
master cytokines such as IL-1β and IL-6 have been shown to independably predict
the presence and the characteristics of the atherosclerotic plaque, whereas novel
markers such as MMPs family including MMP-9 have been shown to be implicated
in its destabilization. Inflammation markers may also provide a tool to follow
atherosclerotic patients to assess their response to different therapies, and then
allow for a better selection of appropriate strategy217,218.
TTP is an anti-inflammatory protein that functions to promote mRNA
decay219. The anti-inflammatory role of TTP has been extensively studied in mouse
models and cell lines, such as blood monocytes and bone marrow–derived
macrophages. The anti-inflammatory functions of TTP have been primarily studied
in rheumatoid arthritis220. However, the role of TTP in atherosclerosis has not been
examined. Our study shows that transplantation of TTP deficient bone marrow into
atherogenic LDLR−/− mice resulted in dramatically increased systemic and multiorgan inflammation. However, atherosclerotic lesion size and plaque composition
were not significantly affected. Surprisingly, bone marrow TTP deficient mice
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displayed a significant reduction in their plasma lipid and hepatic lipid
accumulation, with reduced expression of SREBF-1 in the liver. It remains to be
further determined how serum lipid and hepatic steatosis were severely reduced.
Increased inflammation is counterbalanced by the reduction in serum lipid levels,
resulting in no alteration in atherosclerosis development. This result reveals that
targeting hematopoietic TTP activity may not be a suitable therapeutic approach.
GP-96 is an essential chaperone for folding and function of multiple TLRs
except TLR3. TLRs recognize pathogens and thereby initiate innate immune
response. Deletion of GP-96 results in the post-translational loss of multiple TLRs,
suggesting that this chaperone protein occupies a central position in the innate
immunity. TLRs are implicated in the pathogenesis of atherosclerosis 180,182,193.
Targeting TLRs may provide alternative approaches and new therapy to halt
atherosclerosis. However, evidence for the role of TLRs in atherosclerosis in
mouse models is controversial. Some studies showed atheroprotective effects of
TLRs, whereas others showed pro-atherogenic effects. This discrepancy can be
partially explained by the use of different background strains of the mice 221.
Whether targeting TLRs is a successful approach for the treatment of
atherosclerotic diseases remains to be determined. In this study we show that
bone marrow transplantation of macrophage-specific GP-96 deficient cells into
LDLR−/− mice did not result in any difference in inflammatory status, even though
we confirmed the significant reduction in GP-96 and TLR4 expression in the
peritoneal macrophages. Serum lipid levels were comparable between groups.
Finally, these mice showed no difference in atherosclerotic lesion size and plaque
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composition. Although more details regarding the TLRs function have recently
been studied, the extent to which the different TLRs affect inflammation and
immunity in atherosclerosis remains unclear.
Traditional Chinese medicine (TCM), especially herbal medicine, has been
used for the treatment of cardiovascular diseases for a very long time. Many
compounds from these Chinese herbes are often capable of targeting multiple
pathways. SsnB is a novel bioactive compound isolated and characterized in our
lab; SsnB has anti-inflammatory properties by inhibiting TLR mediated
signaling203,211,215. Inhibiting TLR2/TLR4 signaling pathway may be a fascinating
therapeutic approach for atherosclerosis, however, no TLR2 or TLR4 antagonists
have been approved for clinical use. SsnB has robust anti-inflammatory properties,
but its effect on atherosclerosis is unknown. After super-low dose LPS injection,
LDLR−/− mice showed a slight increase in inflammation and no change in serum
lipid levels. Atherosclerotic lesions were comparable with the control mice.
Furthermore, SsnB treatment had no effects on inflammation and atherosclerosis
after super-low dose LPS injection. These results indicate that SsnB administration
to western diet fed LDLR−/− mice is not effective to change inflammation and
atherosclerosis development when the mice were injected with super-low dose
LPS. The effect of SsnB on inflammation and atherosclerosis in atherogenic mice
warrants further investigation using other animal models.
In conclusion, our studies aimed to test the inflammation hypothesis of
atherosclerosis using various models suggest that the role of inflammation in
atherogenesis is complex. Some novel findings may guide us in future
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investigations. First, we discovered a new role of miR155, a pro-inflammatory
molecule, in promoting vascular calcification, suggesting that targeting vascular
miR155 may be an effective preventive and therapeutic approach for
cardiovascular diseases with vascular calcification as a pathological feature.
Second, we discovered that systemic inflammation resulted from myeloid cell TTP
deficiency surprisingly reduced plasma lipid levels and liver lipid accumulation,
pointing to a possibility that a certain component of inflammation may actually
benefit hepatic lipoprotein metabolism. Third, although TLR signaling has been
implicated in the pathogenesis of atherosclerosis, direct targeting TLRs may not
be an optimal approach for chronic diseases with low-level systemic inflammation,
such as atherosclerosis.
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